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ABSTRACT
Alzheimer’s Disease (AD) is a devastating neurodegenerative disorder affecting
all tissues and cell types of brain leading to emotional dysregulation and cognitive
dysfunction. From genome-wide association studies (GWAS), to date we have identified
forty-two genome-wide significant genes for AD that influence overall disease risk or
endophenotypes, including neuroimaging and gene expression profiles. Nevertheless, the
currently known AD genes do not account for a significant proportion of the heritability
of disease risk, implying the existence of many weak-effect variants in potentially
thousands of genes as drivers of AD outcomes. This genetic architecture, composed of
many small effects, is partly due to the complexity of molecular interaction networks,
where the influence of individual genetic variants is attenuated by overlapping molecular
pathways that are tuned by evolution for robustness. Thus, overcoming the limitations of
GWAS for dissecting the mechanisms of AD requires methods to identify disease
pathways that are enriched for weak genetic effects. Network-based functional prediction
(NBFP) methods use machine learning in gene interaction networks to robustly learn
pathways containing risk genes, which augments the raw statistical signal from GWAS
with biological prior knowledge encoded in a tissue-specific gene network. NBFP
methods have several benefits, including their robustness to statistical noise over raw
GWAS statistics and they enable nomination of functionally relevant candidate genes that
do not themselves carry risk polymorphisms. However, most NBFP methods are
currently limited to single tissues, which is not optimal for complex disorders like AD
that involve many functionally distinct cell types and brain regions. Moreover, there are
now multiple studies of AD endophenotypes, including brain-region specific gene
expression and whole-brain neuroimaging, both paired with genotypes, and single-cell
gene expression data. Thus, there is an additional need for integrative tools that combine
disparate data sources to nominate candidate genes for distinct pathophysiological
processes. In this work, we developed new methods to rank candidate genes based on
multiple disease-relevant networks and to combine gene rankings arising from multiple
sources, including NBFP, imaging GWAS, and gene expression. In our first study, we
applied NBFP to systematically rank AD-risk genes in the hippocampus and amygdala
and developed a novel combined scoring method to integrate these scores with GWAS
associations for low hippocampal and amygdalar volume in patients with AD. Our
method nominated a novel set of region-specific candidate genes primarily involved in
maintaining the stability of the synapse and regulating excitotoxicity. In our second
study, we developed a multi-network-based functional prediction (mNBFP) to allow
multiple source networks. Using three brain-cell-specific networks, our mNBFP approach
outperformed single-network approaches in training performance and achieved high
concordance with recently published AD-GWAS associations. In our third and final study
we integrated our multi-network NBFP and combined scoring approaches with single-cell
gene expression and the Library of Integrated Network-based Cellular Signatures
(LINCS) database to identify potential drug repositioning candidates for AD. We
identified the protein AP1B1 as having strong potential to target an early-AD gene
expression signature, which may yield a novel mechanism for early therapeutic
intervention.
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CHAPTER 1: AN INTRODUCTION TO GENE PRIORITIZATION IN
ALZHEIMER’S DISEASE
Dementia is a broad characterization for a set of related symptoms including loss
of memory, mood disturbances, and many other behavioral abnormalities brought on by
neurodegeneration (Lyketsos et al., 2011; Atri, 2019). A number of neurological and
chromosomal diseases and disorders can lead to dementia including Parkinson’s Disease,
Down’s Syndrome, Alzheimer’s Disease (AD), Traumatic brain injury (TBI), and many
others (Hithersay et al., 2017; Mendez, 2017; Lopez et al., 2019; Taylor et al., 2019).
Despite similarities in emergent phenotypes, the pathology of each disease varies
drastically depending on region of onset and underlying genetic dysfunction (Rossor et
al., 2010; Finger, 2016; Hase et al., 2018).
In 1907, Alöis Alzheimer was working as a neuropsychologist at an asylum in
Frankfurt, Germany when he met the patient August Deter (Alzheimer, 1907; Stelzmann
et al., 1995). At the age of 51, August showed advanced stages of cognitive decline,
presenting with difficulty reading, short term memory impairment, and loss of ability to
use common objects (Alzheimer, 1907; Stelzmann et al., 1995). After she passed, stained
samples of her brain revealed the first amyloid plaques and neurofibrillary tangles which
remain the key posthumous, and increasingly antemortem, biomarkers of the disease.
For many years our understanding of the disease remained phenotypic. Not until
the 1980s did we begin to understand the underlying genetic and molecular factors
driving the onset and progression of the disease. Today we have a firm understanding of
the genes that increase the risk for developing the disease and those which control
familial inheritance. However, full understanding of the molecular underpinnings of the
1

disease and effective therapeutics remain out of reach. Therefore, novel methods for
genetic discovery and drug repositioning are necessary. In the projects described in the
following chapters we have developed innovative new methods for genetic prediction and
drug discovery in the context of AD. We contextualize our predictions in the broader AD
literature and known disease mechanism. Though we developed our analyses in the
context of AD, these approaches have the potential to be applied to any number of
diseases.
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Phenotypic traits and Development of AD
Phenotypic Heterogeneity
In his initial observations of Deter, Alzheimer noted severe short-term memory
loss, inability to read, and loss of some verbal communication skills (Alzheimer, 1907;
Stelzmann et al., 1995). These symptoms compose only a small fraction of the
psychological and behavioral phenotypes that accompany the disease. Commonly,
patients first experience deficits in working memory (Kirova et al., 2015) and long-term
declarative memories (Jahn, 2013). As the disease progresses more episodic memories
(Small and Cochrane, 2020) can be affected as well as speech (Mueller et al., 2018) and
the ability to form and consolidate new memories (Guix et al., 2019).
This specific phenotype occurs due to the atrophy of the hippocampus in the
medial temporal lobe and other limbic system structures that help with memory
consolidation and recall (Pini et al., 2016; Ossenkoppele et al., 2019). For example, one
early sign of the disease is the loss of the sense of smell, or hyposmia, due to the loss of
olfactory neurons (Marin et al., 2018). The smell of a time or place in a memory can help
reinforce and strengthen its encoding (Aggleton and Waskett, 1999; Bruijn and Bender,
2017). The exact cause of hyposmia in patients with AD is not yet fully understood but it
is increasingly used as an additional diagnostic metric to determine if patients with mild
cognitive impairment (MCI) will progress to full AD status (Lafaille-Magnan et al.,
2017).
In addition to memory deficits, AD patients often experience emotional
dysregulation (Ismail et al., 2018). There are several regions of the brain that help
regulate emotion including the amygdala and the prefrontal cortex (PFC). While the
3

amygdala is commonly associated with anger in popular culture, its job is more closely
aligned with regulating the proper emotional response to the present context and has a
long history in the fear-conditioning literature (Gallagher and Chiba, 1996; Phelps and
LeDoux, 2005). The PFC has a number of jobs which usually fall into the umbrella
category of “executive function”. Sub-regions of the PFC control short-term memory,
impulse control, and have a hand in emotional regulation (Jones and Graff-Radford,
2021).
These behavioral and cognitive phenotypes can be quantified through several
different neuropsychiatric exams including the Mini Mental-State Exam (MMSE),
Clinical Dementia Rating (CDR), University of Pennsylvania Smell Identification Test
(UPSIT), and the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD)
(Doty et al., 1984; Fillenbaum et al., 2008; O’Bryant et al., 2008; Arevalo‐Rodriguez et
al., 2015). Each exam probes a different aspect of the behavioral deficits of AD and
application of a full battery of these exams can provide a fairly accurate diagnosis of
premortem AD.
Despite the battery of neuropsychiatric exams, early identification of one
dementia from another can be difficult due to the overlap of symptoms. Some recent
developments in Positron Emission Tomography (PET) and Magnetic Resonance
Imaging (MRI) technology have provided better mechanisms for antemortem diagnose of
AD in patients with cognitive deficits, by leveraging the known biomarkers and
pathology of the disease (Sevigny et al., 2016b). These imaging tools, combined with
neuropsychiatric evaluation, may be an effective method for early identification of the
disease just as we perform mammograms and prostate exams to catch cancer in its early
4

stages. Identification via pathology still faces its own difficulties as pathological
progression is heterogeneous between patients, does not necessarily correspond to the
severity of psychological deficits, and can present differently in individuals with Early
versus Late onset forms of the disease (Koedam et al., 2008, 2010; Ferrari and Sorbi,
2021).

Early versus Late Onset AD
Deter was in her early-fifties when Alzheimer met her in 1907. In most modern
cases of the disease, symptoms present in the mid-to-late sixties with a much smaller
subset presenting between the ages of forty-five and sixty-four (Zhu et al., 2015). These
two broad sub-types of the disease are termed early-onset (EOAD) and late-onset
(LOAD). Symptoms that begin between the ages of forty-five and sixty-four fall into the
category of EOAD (Koedam et al., 2008, 2010). While some patients with EOAD may
have inherited a familial risk gene, familial inheritance represents only a small fraction of
cases (Zhu et al., 2015). Due to its rarity, EOAD is often missed, resulting in missed or
delayed diagnoses and premature deaths (Vliet et al., 2013; Moschetti et al., 2015). The
terrible nature of this fact is compounded by the increased severity of progression in
individuals with EOAD (Koedam et al., 2008). EOAD patients often present with fewer
memory deficits and instead experience more issues with executive function, which may
explain why these cases go undiagnosed for a longer period of time (Palasí et al., 2015;
Joubert et al., 2016). Additionally, there are variations in the pathological biomarkers in
EOAD with less hippocampal atrophy but increased atrophy in the neocortex, which may
also serve to delay an accurate AD diagnosis from imaging (Cho et al., 2013; Migliaccio
et al., 2015).
5

Though the familial inheritance of AD represents a small overall portion of cases,
the genes which drive that inheritance, APP and PSEN1/2, are critical for the build-up of
amyloid plaques and the pathogenic progression of the disease and even play a role in
idiopathic cases of AD. We will discuss their specific roles in pathophysiology in the
next section. The more common case of LOAD is not generally inherited, though
possessing one or more copies of the epsilon-4 allele of the gene APOE drastically
increases the risk of developing the disease (Serrano-Pozo et al., 2021).
This broad variation in phenotypes and time-of-onset makes early identification
difficult, and treatment even more so. The best time to treat the disease is early in
pathogenesis before much neurodegeneration can occur. Identifying that particular point
in time and accounting for all the potential environmental and genetic factors modifying
progression and onset remains a difficult task. Disease onset and progression arise from
the underlying genetic networks driving the pathophysiology. A better understanding of
the disease requires a deeper understanding of those networks and how we can optimally
target them with novel therapeutics.
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The Genetic Landscape of AD
The Genome-Wide Association Study
As of 2022 there are forty-two genes with genome-wide significant risk
associations to AD (Jansen et al., 2019; Wightman et al., 2021; Bellenguez et al., 2022).
While mechanistic studies in model organisms have helped us to better understand the
role of these risk genes, no therapeutic compounds have been developed that effectively
target these risk genes or pathways. The current gold-standard method for gene
prioritization has diminishing returns as we move down the list of candidates and may
limit our ability to identify robust functional, and therapeutically targetable candidate
genes for AD.
Genome-Wide Association Studies (GWAS) identify single-nucleotide
polymorphisms (SNPs) across the study population that are statistically more strongly
associated with having the disease than not (Fig. 1). A build-up of these SNPs in and
around a gene implicate it as a risk gene for the disease (Hayes, 2013). SNPs in a
regulatory region such as transcription start or stop sites can influence whether a gene
gets expressed, while SNPs located inside an exon of the gene may result in a damaging
missense mutation in the protein product leading to a pathogenic phenotype (Shastry,
2009). However, genome-wide significance only tells us that gene has an effect on risk,
but provides no information about the direct role that gene may play in disease onset and
progression, if any (Tam et al., 2019).
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Figure 1: GWAS Overview. Genetic samples are collected from an AD population and a control
population. AD status is determined by a battery of cognitive exams as well as neuroimaging such as MRI
or PET scan. Single variant associations with the disease status are identified across the genome. Due to the
multiple statistical tests run, GWAS significance is extremely prohibitive set at 10e-7. Genes with a buildup of significant risk polymorphisms are designated as disease risk genes. Created with Biorender.com.
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GWAS provides us with a list of candidate genes ranked by the magnitude of pvalue. A reasonable approach to testing these genes is to move down the list from most to
least significant to identify candidate genes, that when perturbed in some way, influence
the disease phenotype. After the first two are three genes, however, there are rapidly
diminishing returns on the level of heritable risk association that GWAS candidates
provide (Boyle et al., 2017; Tam et al., 2019). This phenomenon has been most actively
studied in height, a massively polygenic trait which has accumulated almost 700 genomewide significant risk genes (eMERGE et al., 2014). Work by Pritchard and colleagues in
2019 discusses the diminishing returns of these ever-larger GWAS studies, especially in
the context of complexly inherited traits like height (Boyle et al., 2017). In their
discussion they note that the top genes which reach genome-wide significance, like
APOE for AD, contribute the most to the heritability of risk. As studies grow larger,
incorporating a larger and more diverse genetic cross-section, that list of genes reaching
the stringent levels of significance increases and the total share of heritability begins to
decrease so that a greater proportion of genes is necessary to reach an equivalent level of
heritability that the first two or three genes may contribute on their own (Boyle et al.,
2017).
They conclude by noting that only a small proportion of genes actually have an
effect on disease risk, but the small-world property of genetic networks dictates that most
genes are connected in some way to one or many risk genes and therefore have some
influence on overall disease risk. Many critics of GWAS worry that due to this smallworld property, with a large-enough study, every gene in the genome would eventually
be shown to make some contribution to disease risk (Boyle et al., 2017; Tam et al., 2019).
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Therefore, if every gene is influencing risk in some way, we can leverage those networks
to identify functional clusters of genes which may be optimal candidates for therapeutic
targeting to have the greatest effect on mediating disease severity.

Risk Genes of AD
The major risk factors of AD have been known for over two decades and have
been identified through a mix of GWAS and studies of familial inheritance. The gene
APOE was first identified in studies of familial inheritance in the early 90’s and has been
one of the top risk genes in every GWAS published since the inception of the method
(Corder et al., 1993; Roses and Saunders, 1994; Jansen et al., 2019; Wightman et al.,
2021). As mentioned above, the epsilon-4 allele of APOE conveys a much greater risk for
developing LOAD (Serrano-Pozo et al., 2021). The epsilon-2 allele of the gene appears to
convey protection while the epsilon-3 allele has no protective or deleterious effects
(Corder et al., 1993; Strittmatter et al., 1993). The protein product is involved in
cholesterol transport, the facilitation of lipid transport to neurons, and is involved in the
proper clearance of amyloid plaques from the brain, a process which gets disrupted in AD
(Kim et al., 2009; Bero et al., 2011; De Strooper and Karran, 2016).
While APOE conveys the greatest heritable risk, there are other genes which
contribute directly to the severity of disease onset and progression, namely amyloid
precursor protein (APP) and presenilin 1 and 2 (PSEN1/2) (Armstrong, 2019). There have
been several mutations identified across these three genes which all affect the way that
APP is processed into soluble or insoluble forms of the amyloid- (A) protein
(Cruchaga et al., 2012; Lanoiselée et al., 2017). Missense mutations in APP influence the
efficacy of the various secretase mechanisms to properly cleave APP into its constituent
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intra- and extracellular domains (Kim and Bezprozvanny, 2021). Likewise, mutations in
the presenilins, which act as guide proteins that shuttle APP into the various cleavage
proteins (Pintchovski et al., 2013). Any mutation in these genes could result in missense
mutations which could drive the system towards the production of the larger and more
insoluble A and a build-up of mutations in this pathway could exacerbate symptom
onset and cognitive declines.
Many studies over the past twenty years have confirmed the effect of these
genetic mutations on the inheritance, onset, and progression of AD. Advances in
sequencing and better patient recruitment through large consortia have paved the way for
larger studies that have expanded the list of risk genes beyond APOE. In 2021, the largest
AD MetaGWAS so far was published in Nature Genetics (Wightman et al., 2021). In it, a
group from Denmark collected GWAS data from thirteen cohorts with a combined
1,126,563 patients and identified thirty-eight significant risk loci, seven of which were
newly annotated risk genes for AD (Wightman et al., 2021). Another recent study,
published in April of 2022 performed an integrative genetic analysis incorporating
MetaGWAS candidates and functional candidates promoted using a QTL pile-up method
(Bellenguez et al., 2022). Several of their top candidates were in concordance with the
2021 MetaGWAS, while several other candidates were novel associations to AD
(Wightman et al., 2021; Bellenguez et al., 2022).
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Identifying Novel Disease Genes
As the issues with GWAS prioritization have become more apparent, novel
methods have been developed to address them. A foundational method for functional
disease prioritization from GWAS results is network-based functional prediction (NBFP).
As stated above, GWAS is limited in what it can tell us about the functional importance
of a genome-wide significant hit. Furthermore, a GWAS p-value is blind to the actual
tissue in which the dysfunction of the gene of interest is occurring. NBFP helps to
overcome that issue by using tissue-specific gene interaction networks to leverage
important interactions between risk genes and the rest of the network to identify disease
candidates (Guan et al., 2010) (Fig. 2).
One of the most popular methods for NBFP is Network-wide Association Study
(NetWAS) (Greene et al., 2015). In their initial paper, Greene et al. (2015) explored the
development of their method for using machine learning to identify disease genes based
on tissue-specific networks and discussed the steps that went into the creation of those
networks. Generating robust tissue-specific gene interaction networks often requires
biopsy and sequencing of various organs and cell-types within the body under different
disease conditions. However, some tissues are incredibly difficult to get to and extract a
sample from in living humans, especially the brain and other nervous system structures.
Therefore, they also used a compendium of studies exploring gene co-expression as well
as tissue ontology to determine which genes would be included in each network, and how
they would be connected to one another (Gremse et al., 2011; Greene et al., 2015).
In the end, they generated 144 distinct tissue networks ranging from individual
cell-types like neurons and glia up to full organs like the brain (Greene et al., 2015; Wong
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et al., 2018). In their initial study, they analyzed a hypertension GWAS, a physiologically
and genetically well understood disease, as their test case. Their NetWAS method utilizes
a Linear Support Vector Machine (lSVM) learner to identify functional candidates based
on a True-positive set of genes. This set was composed of the nominally significant
GWAS genes, in their case those genes which reached p < 0.01.

Figure 2: Network-based Functional Prediction Overview. A) Nominally significant GWAS candidates are
identified. Typically, the threshold is set at p < 0.01. B) An appropriate tissue-specific gene interaction
network is identified and the nominal GWAS genes are identified as the “positive” class of genes. C) The
network is represented as an adjacency matrix which as all the genes in the network as columns and rows
and connections are specified as a 1 in a non-weighted network or a value between 0 and 1 in a weighted
network. To identify functional candidates, we want to identify genes connected to the disease risk genes,
so we extract a features matrix which is whole-network by positive genes (indicated by purple-dotted
outline). D) The HumanBase networks are all weighted so connections between two genes are represented
as a value between 0 and 1. There is no true-negative class so non-positive genes are referred to as
“unlabeled”. E) A linear-SVM is trained to identify the positive class of genes based on connections within
the network. This means that some genes initially labeled as positives will be classified as unlabeled as they
are not densely connected to other positive genes, while previously unlabeled genes will now be classified
as positives as they are integral members of disease risk subnetworks.
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In the previous section we discussed the diminishing returns of GWAS as we
move down the list of significance. Genes at a p-value of 0.01 contribute very little to risk
heritability. However, as Boyle et al. (2017) discuss, these higher p-value genes are still
likely to hold biological significance as the small-world behavior of genetic interaction
networks dictates that these genes are likely proximal to genetic risk. NGR takes
advantage of that same feature of these networks and uses this True-positive set of
nominally significant genes to train the network to recognize genes which may not reach
any level of GWAS significance, but are proximal to the genes which convey much of the
disease risk (Guan et al., 2010; Greene et al., 2015).
In their NetWAS paper, Greene et al. (2015) used the Area Under the Receiver
Operator Characteristic (AUROC) Curve (a value from 0 to1) to determine how well
their model performed. Hypertension is a well-studied and documented disease and has a
long list of genes which have been annotated as disease genes based on GWAS, family
studies of inheritance, and other epidemiological studies all cataloged in the Online
Mendelian Inheritance in Man (OMIM) database (Amberger et al., 2015; Hamosh et al.,
2021). This set of genes was used to determine the performance of their model with a
higher AUROC indicating better performance.
They did not expect to have perfect performance, and in fact they did not see
perfect performance, with their best model hitting an AUC of around 0.77. NGR is meant
to identify novel disease genes that likely have not been previously identified because
they are not risk genes or because they are not differentially expressed. A perfect AUC
would indicate that the GWAS results were a perfect set of functional candidates for the
disease and would perhaps only differ from the GWAS in the order they were ranked.
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While not revealing new genes this would support the time, money, and effort put into
conducting GWAS, and would give us a mathematical model for the GWAS results.
As it is, the top GWAS candidates only appear to be part of the story and while
the models are optimized to achieve a high AUC, these studies indicate that the
functionally significant genes are not necessarily those contributing to disease risk. A
higher AUC indicates a more conservative model, meaning the SVM is able to
reasonably tell which genes were originally True-positives based on their connections in
the network and we can be confident that the other genes that would normally be labelled
as false-positives, actually have some functional significance to the disease.
Based on the results from the initial NetWAS model, Greene et al. (2015)
identified IL1B, an immune regulatory gene, as the top functional candidate for
hypertension. To confirm IL1B’s functional role in the disease, they tested its proinflammatory response in cultured Human Aortic Smooth Muscle cells. They identified
the most differentially expressed genes in response to the up-regulation of IL1B in the
cells and observed that the top functional candidates from their blood-vessel network
results closely replicated what they observed in vitro.
The NetWAS paper has been the most high-profile NBFP paper published to-date
and it has laid the groundwork for many other attempts at NBFP, and has even been
applied to other disease cases, including AD. However, the two AD NBFP papers were
primarily methods-based and did not develop actionable hypotheses for candidate genes,
though they laid the ground work for effective NBFP in AD by considering the use of
novel machine learning mechanisms and exploring the use of endophenotypes (Song et
al., 2016; Yao et al., 2017).
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Identifying candidates for sub-phenotypes of disease
An endophenotype is an underlying pathophysiological feature of the disease like
a biomarker or a behavioral or physical feature. In the case of AD, endophenotypes
include total brain volume as well as regional volumes and PET quantification of brain
activity and amyloid plaque build-up (Flint and Munafò, 2007). After the initial NetWAS
paper, Greene and colleagues were quick to explore the efficacy of endophenotypes for
functional prediction in AD using data from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) (Petersen et al., 2010; Weiner et al., 2015; Song et al., 2016). This
project had two goals: First, to determine if using statistics from an endophenotype
GWAS would improve prioritization of a gold-standard set of genes over a set of
permuted scores and GWAS. The second goal was to determine the efficacy of AD
endophenotypes for future analysis with this method.
Song et al. (2016) ran two parallel analyses, mirroring the two ADNI phases with
both genome scan and hippocampal volume information available. In the case of the
ADNI-1 cohort their model performed better on average than GWAS at promoting their
gold-standard set of genes compiled from disease gene annotations on OMIM (Amberger
et al., 2015; Hamosh et al., 2021). For the ADNI-2 cohort GWAS performed slightly
better than the average NetWAS scoring, though in all cases the NetWAS method
significantly outperformed the permuted scores. They identified several genes in the
protocadherin cluster, which was a novel result for a NetWAS analysis and for AD. They
hypothesized that since all the genes were from the same family, they likely had similar
patterns of connectivity, making it difficult for NetWAS to distinguish between the genes
and determine which was most closely associated with the disease.
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Song et al. (2016) only briefly discussed the protocadherins and did not make any
hypotheses about the potential of these genes to be functional candidates for AD. They
used their results as a warning for genes of the same family to potentially be spurious
results, but more importantly to show that using AD endophenotype GWAS are a valid
path forward for functional prioritization in the disease case, even calling for future
studies to continue the work.
In fact, a year later the group published a second study examining the efficacy of
amygdalar florodeoxyglucose (FDG)-PET quantification, a measure of brain activity, as
the endophenotype for a new NBFP (Yao et al., 2017). In addition to this analysis, they
tested several new machine learning methods to determine if improvements in accuracy
could be made with a new learning tool. This was an interesting avenue of experimental
exploration as earlier work has shown that the linear SVM yields the optimal
performance for NBFP (Guan et al., 2010). However, one drawback of generic NetWAS
is that the statistical information provided by the continuous p-values assigned to genes
from GWAS gets lost in the hard cutoff to determine the significant and non-significant
groups of genes. As discussed above, this information has a diminishing return on
investment as the p-value increases, but nevertheless those genes have some biological
association to the disease, or in the case of this study, to the endophenotype.
Yao et al. (2017) proposed the use of several regression methods including Ridge
regression with SVM and Support-Vector regression (SVR) to take advantage of the
continuous p-value space provided by the GWAS. This approach also allowed them to
address another limitation of gene prioritization which is where to draw the line in the list
of newly ranked genes to look at in follow-up experiments. First-principles dictate that
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the top ranked gene and perhaps two or three after it are excellent candidates, but the
genes after that also possess high scores and are also reasonable candidates for
consideration. A more effective and actionable approach considers modules of top ranked
genes and identifies their functional pathways to determine their association to disease,
and their potential for uncovering more about the biological underpinnings of the disease.
Therefore, in addition to the added regression learning approaches, Yao et al. (2017)
implemented a module prioritization approach to not only consider the top few genes, but
whole modules of robust functional candidates.
Their results were compelling and indicated that a regression approach had the
potential to outperform a linear SVM at building models to reprioritize a gold-standard
set of disease genes. The difference in performance, however, was marginal so we
believe further analyses of different machine learning methods for NBFP is necessary.
The module analysis revealed tightly connected modules of genes with reasonably high
connection weights, with Ridge regression yielding the greatest number of connections
between its top genes (Yao et al., 2017).
Their module analysis highlights a key feature of NetWAS, and NBFP in general,
that exposes a major drawback of GWAS for gene prioritization. As we have discussed,
the logical step post-prioritization is to pull the top few genes for follow-up analysis.
However, as the module analysis from Yao et al. (2017) shows, many of the top
functional candidates post-NetWAS were ranked incredibly low in the initial GWAS,
with many top genes in the Ridge results from below the 200th rank in GWAS. So, their
method not only highlights the potential for novel NBFP approaches with new learners,
but it also proposes a robust module prioritization approach that could provide more
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actionable sets of genes that would never be considered by GWAS p-value alone.
These two papers laid the groundwork for NBFP in AD while exploring new
spaces for methodological innovation, especially in terms of the way we leverage
available endophenotypic measures of the disease and the methods we implement to rank
the final candidates. Though they are foundational to NBFP methods development in the
context of AD, they stopped short of actionable gene prioritization for novel therapeutic
targets and mechanistic discovery. The work in this dissertation builds on their
momentum and performs and in-depth exploration of the prioritized genes and pathways,
while adding our own mechanistic insights. Though learner improvements and better
module identification are critical components for improving NBFP in AD, a major
remaining limitation exists in the actual networks being used.
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Advancing Functional Prediction Through a Multi-Network Approach
AD is a complex neurological disorder that has heterogeneous genetic and
phenotypic features. While it is a disease of the brain, the brain itself is a heterogeneous
structure made up of a diverse range of cell-types and sub-regions with different
metabolic requirements and functional purposes. Due to this complexity of tissues, there
is no a priori best choice for network when performing NBFP in AD, unless, for
example, one has performed an endophenotype GWAS analysis. In the case of Song et al.
(2016) and Yao et al. (2017), the hippocampus and amygdala networks were the
respective best choices for those phenotypes.
Endophenotype GWAS are highly specific and have very low N’s. It is more
likely that new NBFP studies will take advantage of the many recently published AD
MetaGWAS discussed above, but with case-control data the choice of network is not
clear. Certainly, the whole-brain network is a reasonable choice, but many of the changes
in AD, at least at the early stages, are localized to specific regions like the frontal and
temporal lobes. Even in these lobes the damage is localized. The temporal lobe often sees
initial damage to the medial region as the hippocampus begins to degrade while the PFC
often sees more atrophy in the dorsolateral PFC. These regions are still not the lowest
functional unit of the brain as each is comprised of inhibitory and excitatory neurons,
astrocytes, oligodendrocytes, and microglia. Each of these is affected by AD in myriad
ways from microglial and astrocytic activation which drives chronic neuroinflammation
in neurons which succumb to excitotoxicity driven by A accumulation and oxidative
damage (Parsons and Raymond, 2014; Hansen et al., 2018; Liu et al., 2019; Leng and
Edison, 2021).
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Each of these cell types has been studied in-depth as the potential starting point
for disease pathology, but the reality may be less sequential (Cai et al., 2013; Fakhoury,
2018; Hansen et al., 2018; Stolero and Frenkel, 2021; Tajbakhsh et al., 2021). All of
these cell-types have the potential to initiate the pathological progression of AD whether
it be in response to amyloid accumulation, or an inflammatory event that kick-starts that
accumulation (Parsons and Raymond, 2014; Heneka et al., 2015). So, in the case of
MetaGWAS it is impossible to determine the most relevant network. There are many
potential correct answers and the choice may depend on the specific biological question
at hand. However, we propose that the correct choice can be all of the above. In chapter
three of this dissertation, we explore the validity of a multi-network approach to NBFP
which considers the connections within all relevant networks to identify robust functional
candidates.
While this approach is novel to AD, we are not the first group to attempt a multinetwork NBPF. The most high-profile of these methods is called Simultaneous Inference
of GeNEs and Tissues (SIGNET) (Wu et al., 2017). Their method utilized networks
which not only considered gene to gene interactions but also incorporated transcription
factor interaction information (Marbach et al., 2016). They implemented a Bayesian
Markov Random field learner to identify top functional candidates (Lin et al., 2015,
2016). They compared their rankings to those from state-of-the-art NetWAS, GWAS pvalue, and a single-network version of their method at prioritizing genes annotated to AD
in DisGeNET, another disease gene annotation database (Piñero et al., 2017). They tested
their approach in several complex disease cases including Schizophrenia and Multiple
Sclerosis, among others (Wu et al., 2017). It was interesting to note that their method
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tended to perform better on non-central nervous system diseases like Crohn’s and
Ulcerative Colitis than it did on disease like MS or Schizophrenia, where NetWAS either
performed as well or significantly better than their multi-network approach.
Despite the varied performance, they also went beyond the single ranked genes
and performed pathway enrichment analysis for their method and compared them to those
from GWAS rankings. They observed that while both gene sets shared many important
disease terms like CNS and brain development for Schizophrenia, those terms had
elevated significance in the SIGNET prioritizations indicating more of the functional
candidates fell into those pathways.
This paper was an excellent proof of concept that showed the validity and
potential of a multi-network approach to NBFP in complex diseases. In addition to their
success implementing the multi-network approach their learning method and networks
were novel. As they point out in their discussion, there is still plenty of room for
innovation in the network space of NBFP. There are myriad ways that two genes might
be connected, co-expression and transcriptional regulation being only two, as well as
many regulatory mechanisms like histone methylation or deacetylase proteins, which can
increase or severely limit expression of genes. Linkage disequilibrium also plays a role in
the statistical association of genes physically close on the same chromosome have to
disease status. This is part of the reason why many genes on chromosome 19, where
APOE resides, have such strong associations to AD. Our current networks provide a
workable but incomplete map of genetic interactions in the various tissues, especially as
many of the connections are inferred from tissues that are impossible to biopsy.
Incorporating more of this information into the tissue-specific networks being used may
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help NBFP methods to better identify strong leverage points in the network for treatment
and better mechanistic understanding of the disease. While this remains an important
future direction for NBFP research it is not a focus of this study and we remain confident
in the efficacy of our current networks for the purpose of identifying novel disease
pathways that will lead to actionable therapeutic targets.
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The Drugs of AD
Drug development in AD has been fraught with hundreds of failed trials and
approved drugs with horrible side-effects over the past forty years (Cummings et al.,
2014, 2020). There are currently 6 approved compounds to address various aspects of AD
symptoms from cognitive deficits to sleep disturbances: donepezil, memantine,
rivastigmine, galantamine, suvorexant, and the recently approved aducanumab (Rogers
and Friedhoff, 1996; Rösler et al., 1999; Wilkinson et al., 2001; Reisberg et al., 2003;
Sevigny et al., 2016a; Hamuro et al., 2018). The drug tacrine was the first drug approved
for use in AD but was quickly discontinued due to its hepatoxicity (Breijyeh and
Karaman, 2020). Though the drugs that maintain their approval are less toxic than
tacrine, they have their own negative side-effects including nausea, vomiting, confusion,
dizziness, and stroke (Sevigny et al., 2016a; Breijyeh and Karaman, 2020). Even if a drug
provides some relief to cognitive symptoms, some patients may have to deal with qualityof-life altering side-effects that make long-term use of the drug untenable.
Many of these drugs are acetylcholinesterase inhibitors which slows the
degradation of acetylcholine in the synapse leading to increased binding of the signaling
molecule to the post-synaptic cell (Rogers and Friedhoff, 1996; Rösler et al., 1999;
Wilkinson et al., 2001; Reisberg et al., 2003). While this is an excellent strategy to
maintain signaling between critical neurons, acetylcholine receptors are prolific in the
body with particularly high density in the gut and muscle tissues, leading to side-effects
of nausea and vomiting. The off-target effects of our current treatment options were
likely a major contributing factor to the mass movement to the drug Aduhelm
(aducanumab) when it was controversially approved by the FDA in June of last year
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using the rapid approval pipeline, even after the review committee voted almost
unanimously to not approve it (Sevigny et al., 2016a; Howard and Liu, 2020).
Aducanumab is a monoclonal antibody designed to bind to amyloid plaques to aid
microglia in clearing the plaques from the brain (Sevigny et al., 2016a). Based on the
florbetapir (FBP)-PET imaging, a measure of amyloid burden in the brain, the drug was
incredibly good at achieving that goal, with patients showing a dramatic decrease of
amyloid plaques after a year of treatment. However, the plaques may only be a byproduct
of the underlying pathogenic processes and their removal will not necessarily lead to
improvements in cognitive function. Indeed, while the FDA fact sheet states that patients
saw dramatic improvement in cognitive function, the published results appear to be less
conclusive (Sevigny et al., 2016a). Only the highest dosage treatment group saw a
significant difference from baseline in cognitive function. Unfortunately, one major sideeffect of this treatment was brain swelling, and in some severe cases edema was reported.
Concerningly, that outcome was most often observed in patients with the APOE-4 allele,
meaning the group in greatest need of the treatment would also face the greatest risk for
adverse events from that treatment (Sevigny et al., 2016a; Howard and Liu, 2020).
Though the amyloid cascade hypothesis has a lot of traction in the AD literature
(Hardy and Higgins, 1992; Karran et al., 2011; Barage and Sonawane, 2015), clearing
amyloid at a late stage of the disease, when many patients begin to seek treatment, may
not have the desired benefits to cognitive outcome. The emergent behavioral phenotypes
of AD patients are a direct result of loss of neurons in key brain areas, exacerbated by
inflammation due to microglial and astrocytic activation (Draganski et al., 2013). Both
soluble and insoluble amyloid plaques have noted roles in both neuronal cell death and
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microglial and astrocytic activation (Favit et al., 1998; Price et al., 2014; Beckman et al.,
2019), so clearance is a logical treatment option. However, removing amyloid at a late
stage of AD cannot return neurons that have already died. As many patients who would
be pivoting to this incredibly expensive drug would be in the later stages of the disease,
the drug may only provide temporary alleviation of cognitive deficits perhaps as a result
of decreased glial-induced-inflammation from the lower levels of amyloid.
We are then faced with a treatment dilemma. Perhaps at an earlier stage of the
disease, drugs like Aduhelm could have a measurable benefit on disease development and
progression, perhaps extending a patient’s cognitive health by years. After a certain
timepoint, however, there must be a biological tipping point which makes a drug like
Aducanumab ineffective. To better identify and develop effective therapeutics we need to
better leverage available genetic and phenotypic data.
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Leveraging Genetic Data to Identify Novel Therapeutics
Creating, testing, and implementing a novel compound is a long and expensive
process. The average cost of developing an AD drug is close to 6 billion dollars, almost
six times as much as the average cost to develop a cancer drug and two times more than
the pharmaceutical industry average (Fig. 3) (Cummings et al., 2014, 2020). This remains
one of the biggest roadblocks for drug development in AD and likely why Aducanumab
is the first drug to be approved for AD in over a decade. One potential method for cutting
down on costs and speeding up the process of clinical trials and delivery to patients is a
method called drug repositioning (Corbett et al., 2012; Ballard et al., 2020).
Drug repositioning is the process of identifying a strong candidate drug for your
disease case that already has FDA approval in another. Though diseases have diverse
phenotypes that make them distinct from one another, the underlying genetic networks
can break in the same pathways, meaning that a drug that works for seizure disorders,
may be beneficial in AD. There have been several famous cases of successful
repositioned drugs including thalidomide, the teratogenic contraceptive, to cancer and the
antiviral amantadine to Parkinson’s Disease (Hubsher et al., 2012; Stewart, 2014).
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Figure 3: Graphical comparison of the average cost to develop a single therapeutic compound for
Alzheimer’s, Cancer, and the pharmaceutical industry average. The cost of developing an AD drug is
roughly 5.8 billion dollars, six times higher than the 800 million it takes to develop a cancer drug and twice
as much as it costs to develop a drug across the pharmaceutical industry.

Early implementations of drug repositioning needed to rely on knowledge of
common pathways and mechanism, restricting blue-sky approaches that might look in
odd places for a novel compound. One method that has helped expand our ability to
utilize genetic signatures for drug repositioning is the tool Connectivity Map, now the
Library of Integrated Network-based Cellular Signatures (LINCS), first developed by the
Broad Institute in 2006 (Lamb et al., 2006; Subramanian et al., 2017). The first iteration
of Connectivity Map took a collection of immortalized cell lines and exposed them to a
diverse range of therapeutics and perturbagens at varying concentrations for different
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lengths of time. The cells were then sequenced and the resulting differential expression
was registered for that compound, concentration, exposure time, and cell type as its
genetic signature.
Those genetic signatures are then stored and can be queried. The query requires a
set of up tags and down tags, often derived from differential expression analyses. The
newest iteration LINCS, has developed a connectivity score that helps determine strength
of correlation, or anti-correlation, a given compound has with the submitted tag lists
(Subramanian et al., 2017) (Fig. 4). This allows scientists trying to identify potentially
effective therapeutic candidates for their disease case, or even compounds that will help
induce a desired phenotype to find a set of candidate drugs they can build novel
hypotheses around.
There has been a concerted effort over the past decade to increase drug
repositioning for AD. A Delphi consensus in 2012 queried several subject matter experts
to rank top candidate drugs for repositioning based on mechanism of action, brain
penetration, safety, and whether preclinical dosages where equivalent to those that would
be used in humans (Corbett et al., 2012). This study revealed a set of five families of
compounds many of which were treatments for heart disease like calcium channel
blockers and angiotensin receptor blockers (Corbett et al., 2012). A subsequent study
conducted from 2018-2019 identified fasudil, a ROCK inhibitor, antivirals, and the
acetylcholinesterase inhibitor phenserine as strong candidates for repositioning to AD
(Ballard et al., 2020). While all of these drugs appear to be strong candidates based on the
criteria above, there have been no follow up studies in AD or MCI patients to assess their
tangible benefit to cognitive health or their tolerance in an AD cohort.
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Figure 4: Overview of the original Connectivity Map. A) A biological signature is obtained. This signature
usually takes the form of differential expression data from cells, model organisms, or human studies. A set
of up tags and down tags is identified based on up- and down-regulated genes. B) The Connectivity Map
and LINCS have a set of reference gene expression profiles for thousands of perturbagens. The submitted
biological signature is queried against the set of reference profiles and connectivity scores are calculated
based on the strength of correlation. C) Drug candidates are assessed based on positive or negative
connectivity scores to the submitted biological signature. For a disease like AD, the ideal candidate would
likely have a negative correlation with disease expression and would effectively reverse the aberrant gene
expression. Created with Biorender.com

Drug discovery for AD using LINCS has faced its own data-availability
challenges, though that is changing. Groups like the ADNI, the AD Knowledge Portal
and the UK Biobank all have genetic information for AD, MCI and Control patients. This
data, however, was collected on a number of different platforms and comprises many
different sample sizes and diverse genetic populations. One recent study implemented the
searchable, platform independent expression database (SPIED) to coalesce the AD
genetic signatures from across the field and submitted them to LINCS (Williams, 2013;
Ballard et al., 2019).
They identified a total of seventy-eight compounds which they assessed using six
different in vitro assays designed to mimic AD pathophysiology. Of the seventy-eight,
30

nineteen showed improvements to molecular AD phenotypes and a further eight of those
drugs are known to penetrate the brain (Ballard et al., 2019). Some of the top candidates
included an -1 adrenergic receptor antagonist, an antibiotic, and a histamine H2receptor antagonist. While none of these drugs have been tested in a model organism they
hold promise and show that LINCS is a viable method for identifying novel therapeutic
compounds for AD.

The Next Stages of Gene and Drug Discovery in AD
The methods discussed throughout this chapter are on the cutting edge of gene
prioritization and drug discovery. Innovations in NBFP will provide greater insight into
the genetic leverage points within disease tissues which will further clarify the most
optimal path forward for drug repositioning. The next several years will lead to
refinement of the multi-network approach for NBFP and see it applied not only to AD,
but a range of complex disorders. Finally, while these methods improve and enrich
GWAS results, the advancements we have seen over the past decade in this space has
been due, in part to the immense volume of data collected by AD consortia. The genesis
of large-scale initiatives like ADNI, AD Knowledge Portal, and the UK Biobank have
lowered the barriers of access to high-quality genetic data allowing small labs like ours
that would never have the resources or person-power to conduct large-scale genomic
studies to still make meaningful contributions to the field. I hope in the coming years that
advancements in NBFP will help inform the collection of new GWAS data to ensure that
our genes and drugs are effectively treating the full spectrum of the disease.
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Introduction
The central goal of genome-wide association studies (GWAS) in Alzheimer’s
disease (AD) is to identify novel candidate genes influencing risk for developing AD. Like
other complex disorders, AD has highly polygenic risk, where hundreds or even thousands
of small-effect alleles modify the probability of developing AD (Lee et al., 2013; Carmona
et al., 2018). Fundamentally, this genetic complexity arises from the underlying biological
complexity of AD, where all the major cell types of the brain and multiple highly
differentiated brain structures have established roles in pathogenesis or symptom severity
(Calderon-Garcidueñas and Duyckaerts, 2017; Jaroudi et al., 2017). To fully capture this
biological complexity for genetic mapping, the international community has undertaken
multiple strategies, including case-control GWAS and imaging GWAS, that capture distinct
components of the genetic risk for AD. In particular, case-control GWAS is well powered
to detect risk alleles but cannot ascribe these effects to specific brain pathologies. On the
other hand, imaging GWAS can localize the effect of alleles, but these studies have limited
sample size and, therefore, limited statistical power. In this study, we apply a networkbased gene reprioritization (NGR) strategy that leverages mature functional prioritization
methods to integrate AD risk-gene networks from case-control GWAS with imaging
GWAS data to predict genes that specifically influence hippocampal and amygdalar
atrophy.
The spectrum of AD risk alleles is well studied, particularly in European
populations (Hu et al., 2017; Solomon et al., 2018; Jansen et al., 2019; Rajan et al., 2019;
Andrews et al., 2020). Using gold-standard cognitive exams that provide robust premortem
diagnoses of AD, modern case-control GWAS are powered to detect small-effect alleles
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using large cohorts. These efforts have culminated most recently in a meta-analysis of AD
GWAS assessing the effect of 9,862,738 SNPs in 71,880 cases and 383,378 controls
(Jansen et al., 2019). With such large-scale studies, it has been possible to detect 2,357
variants and 29 genes with genome-level significant associations to AD (Jansen et al.,
2019). However, increasing population size has diminishing marginal returns. Newly
resolved effects are ever weaker. Moreover, the functional role of these alleles cannot be
localized to any of the relevant cellular or regional drivers of AD pathology based on casecontrol status alone. Nevertheless, with a valid AD diagnosis as an endpoint, the alleles
mapped in case-control GWAS can be confidently attributed to AD risk.
As an alternative to large case-control studies, the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) uses structural magnetic resonance imaging (MRI) as a
phenotype for GWAS (Wyman et al., 2013). In contrast to cognitive exams, which measure
the complex emergent functions of distributed neural circuits, neuroimaging localizes
particular structural pathologies. In principle, alleles that have a small overall effect on
disease risk could have a comparatively stronger effect on critical pathologies, including
hippocampal and amygdalar atrophy, that mediate the genetic risk factors for developing
AD. However, MRI is expensive and time-consuming, so the ADNI sample size is limited
to the thousands, not hundreds of thousands, of subjects. To date, 2272 patients have been
recruited, a subset of 556 of which have both imaging and genotype data (ADNI-1 cohort)
(Weiner et al., 2015). This dramatically limits statistical power relative to case-control
GWAS. Moreover, while some longitudinal data have been gathered (Bhagwat et al.,
2018), it is currently impossible to dissociate background developmental differences in
brain structures from pathogenic changes due to AD. Thus, for example, alleles influencing
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the growth of the hippocampus cannot be distinguished from alleles that exacerbate
hippocampal atrophy.
To leverage the independent strengths of case-control and imaging GWAS, we
performed an integrative analysis. Using NGR with the well-powered case-control metaGWAS (Jansen et al., 2019), we identified hippocampus- and amygdala-specific functional
networks that were enriched for AD risk genes. We then used a novel approach to combine
these functional results with imaging GWAS results for low hippocampal and amygdalar
volume in patients with AD. By combining AD specificity from NGR with genetic
influences on low hippocampal and amygdalar volume, we can prioritize high-confidence
genes for AD-induced hippocampal and amygdalar atrophy.
The key insight to NGR is that the tail of low p-values from a GWAS is typically
highly enriched for genes in disease-relevant biological processes, independent of whether
most of those genes achieve genome-wide significance (Greene et al., 2015). For any
choice of statistical cutoff there is a tradeoff between (a priori unknown) false positives
and false negatives. In particular, genome-wide significance is a conservative threshold
that has many false negatives. With a more liberal threshold, one captures more true
positives at the cost of more false positives, with no way to discriminate one from the other
using GWAS data alone. In order to distinguish likely true positives from false positives,
NGR augments the GWAS statistical signals with functional gene-gene interactions. The
essential idea of NGR is that true positive genes, by virtue of being functionally related to
the disease, are likely to be functionally related to each other. By identifying subnetworks
that are enriched for interactions among nominally significant GWAS genes, we can
distinguish the likely true positives from spurious associations. Several approaches to NGR
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have been recently developed, including strategies based on support vector machines
(SVM) (Greene et al., 2015), network diffusion (Li and Li, 2012), and Bayesian data
integration (Wu et al., 2017). All methods return a functional score for every gene in the
genome (a reprioritization) that measures how strongly each gene interacts with the
nominally significant GWAS hits. Using NGR, many groups have shown significant
improvements in disease gene prediction (Greene et al., 2015; Wu et al., 2017), including
in AD (Song et al., 2016; Yao et al., 2017).
In this study, following Guan et al. (Guan et al., 2010), we used an ensemble of
SVMs to reprioritize AD risk genes from case-control GWAS using hippocampus- and
amygdala-specific functional networks. We then integrated these tissue-specific functional
scores with imaging GWAS p-values for hippocampal and amygdalar volume. Using a
combined score based on the joint cumulative density function of functional scores and
imaging GWAS p-values, we prioritized candidate genes for hippocampal and amygdalar
atrophy in AD and defined the putative AD gene networks in which these candidate genes
function.
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Methods
Data
We used two distinct GWAS data sets and processed them through separate
pipelines (Fig 1). The first data set is from the ADNI database and includes genotype and
structural MRI imaging data (adni.loni.usc.edu). The ADNI was launched in 2003 as a
public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The
primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI),
positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of mild
cognitive impairment (MCI) and early AD. Identifying novel biomarkers of AD will help
aid clinicians and researchers develop effective treatments and interventions.
ADNI is the result of efforts of many co-investigators from a broad range of
academic institutions and private corporations, and subjects have been recruited from over
50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 subjects
but ADNI has been followed by ADNI-GO and ADNI-2. To date these three protocols, in
addition to the ongoing ADNI-3, have recruited over 2200 adults, ages 55 to 90, to
participate in the research, consisting of control, non-AD (CN) older individuals, people
with early or late MCI (EMCI or LMCI), and people with early AD. The follow up duration
of each group is specified in the protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects
originally recruited for ADNI-1 and ADNI-GO had the option to be followed in ADNI-2.
Thousands of longitudinal imaging scans (Jack et al., 2008; Jagust et al., 2010),
performance on neuropsychological and clinical assessments (Petersen et al., 2010) and
biological samples (Shaw et al., 2009) were collected at baseline and at follow-up visits for
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all or a subset of participants. Genome-wide genotyping data (Saykin et al., 2010) are
available on the full ADNI sample. For up to-date information, see www.adni-info.org.
Freesurfer version 5.1 was used to extract hippocampal volume and amygdalar
volume measures from the 1.5 T baseline MRI scans of the ADNI-1 participants as
described previously(Risacher et al., 2013). The measurements were retrieved from the
ADNI data archive.
Genotype data of all participants from ADNI-1 were downloaded, quality
controlled, and imputed to get full coverage beyond the initial 600,000 SNPs available on
the Illumina 610Quad platform. Initial QC was performed using PLINK 1.9
(https://www.cog-genomics.org/plink2/) (Chang et al., 2015). Genotype data were
processed as follows: 1) Samples missing more than 10% of their genotype calls were
removed (1 person removed), 2) SNPs with a minor allele frequency (MAF) greater than
0.05 were filtered for samples missing greater than 5% of the genotype calls and those with
an MAF less than 0.05 were filtered for samples missing greater than 1% of genotype calls
(48,026 variants), 3) duplicated samples were removed (14,238 variants), 4) samples that
failed Hardy-Weinberg Equilibrium (HWE) (p < 10-7) were filtered out (434 variants
removed). After QC, we performed genotype imputation using BEAGLE 5.1
(http://faculty.washington.edu/browning/beagle/beagle.html) (Browning et al., 2018).
Briefly, genotype data were split by chromosome and each chromosome was mapped onto
the appropriate reference genome (hg37) and imputed to the CEU 1000 Genomes Project
(1000 Genomes Project Consortium et al, 2015) reference panel. Imputed chromosomes
were recombined using PLINK 1.9 and underwent an additional round of QC following
the procedures listed above (433 variants removed for not meeting HWE). After
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imputation, 14,403,717 variants and 683 samples passed QC. Hippocampal and amygdalar
volumes were used as the phenotypes in two separate GWAS analyses. A total of 556
individuals had both genotyping data and imaging phenotype data (n = 120 AD, n = 261
MCI, n = 175 CN). Genome scans were performed using PLINK 1.9 using a linear
regression model with covariates for age, sex, education, and intracranial volume (ICV),
following the GWAS protocol of a recent ADNI study using a related network-based gene
reprioritization approach (Song et al., 2016).
SNP-level p-values were mapped to gene level p-values using MAGMA
(https://ctg.cncr.nl/software/magma) (deLeeuw et al., 2015). SNPs were annotated to genes
using the hg37 genetic reference and a 10kb annotation window on either side of the gene.
The window size was chosen to match that used for gene mapping the AD meta-GWAS
study (Jansen et al., 2019). Of the 14,403,717 SNPs contained within the ADNI genotype
data, a total of 6,989,349 SNPs mapped to 18,385 genes. The HV GWAS yielded 338
nominally significant genes and 3 genes that reached a Bonferroni-Holm corrected,
genome-wide significant p-value (Supp. File 1). The AV GWAS yielded 276 nominally
significant genes and 1 gene that reached a Bonferroni-Holm corrected genome-wide
significant p-value (Supp. File 2).
The second data set we analyzed was the AD meta-GWAS study conducted previously
(Jansen et al., 2019). In that study, Jansen et al. performed a meta-analysis on case-control
AD data from four major studies including the Alzheimer’s disease working group of the
Psychiatric Genomics Consortium (PGC-ALZ), the International Genomics of
Alzheimer’s Project (IGAP), the Alzheimer’s Disease Sequencing Project (ADSP), and
UK Biobank (UKB). This analysis resulted in 71,880 AD cases and 383,378 non-AD
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controls and 9,862,738 SNPs passing quality control. SNP associations were calculated by
regression as follows:
1. Logistic regression was used to calculate SNP association with case control
phenotypes from ADSP, PGC-ALZ, and IGAP.
2. Linear regression was used to calculate associations for a continuous phenotype
from UKB (calculated as the number of parents with AD).
3. Associations were adjusted for sex as well as age. However, the ADSP study did
not use age as a covariate as the study group was highly enriched for older patients
and inclusion of age as a covariate in that study eliminated true AD associations
(see Methods: Data Analysis in (Jansen et al., 2019)).
4. The first four ancestry principal components (PCs) were also used to adjust
statistical associations. A total of 20 were calculated and more were used if they
showed a strong association with the phenotype.
5. For UKB 12 PCs, age, sex, genotyping array, and testing center were all used as
covariates.
SNP summary statistics were downloaded from the Center for Neurogenomics and
Cognitive Research website: https://ctg.cncr.nl/software/summary_statistics. We used
MAGMA to compute gene-level p-values as above. Of the 13,367,299 SNPs contained
within the meta-GWAS summary statistics, 6,536,525 mapped to a total of 18,456 genes.
At a nominal level of significant (p < 0.01) the meta-GWAS had 735 significant genes,
while a Bonferroni-Holm corrected p-value yielded 28 genome-wide significant genes
(Supp. File 3).
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Network-Based Gene Repositioning
To functionally score every gene in the genome for relevance to AD, we performed
NGR. NGR requires two inputs: a set of positive examples of disease-associated genes,
and a functional network encoding gene-gene interactions (cf. (Greene et al., 2015)). From
these data, NGR uses the network to propagate the “disease-associated” annotation to genes
that are well connected to the disease-associated gene set. In this study, we used nominally
significant AD-GWAS genes (p < 0.01) from the MAGMA analysis of the meta-GWAS
as disease-associated genes. For functional networks, we used the hippocampus and
amygdala tissue-specific functional networks freely available for download at HumanBase
(https://hb.flatironinstitute.org/download;

‘hippocampus_top’

and

‘amygdala_top’)

(Wong et al., 2018). Briefly, these networks were generated using a regularized bayesian
knowledge integration based on tissue ontology and a combination of gene expression
datasets from the Gene Expression Omnibus (Barrett et al., 2013) representing 20,868
conditions (Greene et al., 2015). Each functional network is a weighted network, where
each pair of genes (gi, gj) is linked with a weight, 𝑊𝑔𝑖 𝑔𝑗 , encoding the predicted probability
that those genes functionally interact in that tissue. We define a feature vector, fg, for each
gene, g, in the genome as the vector of weights connecting g to the n AD-GWAS genes,
𝑝1 , … , 𝑝𝑛 (i.e., positive examples),

𝑓𝑔 = [𝑊𝑔𝑝1 , … , 𝑊𝑔𝑝𝑛 ].

Using these feature vectors, we trained an ensemble of 100 (linear) support vector
machine (SVM) classifiers to distinguish between AD-GWAS genes and the rest of the
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genes in the genome. Formally, this problem is an instance of positive-unlabeled (PU)
learning (PU), as we only have positive examples of AD-relevant genes (i.e., GWAS hits),
but the status of all other genes is unknown. In the PU learning setting, we can treat all
unlabeled examples as negatives for the sake of training the model, with the understanding
that many unlabeled examples are likely AD-associated genes (Elkan and Noto, 2008). For
each of the 100 SVMs, we trained using all positive examples and a random, balanced set
of unlabeled examples as putative negatives. Each SVM was cross-validated to optimize
its cost hyperparameter, C, over a grid, as described previously (Tyler et al., 2019). Each
model Mi assigns each gene, gj, a model-based, real-valued prediction score Mi(gj), where
large positive scores correspond to high confidence that the gene is a positive example and
negative scores correspond to low confidence. To normalize prediction scores across
models prior to aggregation, we computed an unlabeled-predicted-positive rate (UPPR)
for each model, Mi, and gene, gj, as

UPPR ij =

#{𝑔 ∈ 𝑈𝑛𝑙𝑎𝑏𝑒𝑙𝑒𝑑 | 𝑀𝑖 (𝑔) > 𝑀𝑖 (𝑔𝑗 )}
#{𝑔 ∈ 𝑈𝑛𝑙𝑎𝑏𝑒𝑙𝑒𝑑} | 𝑀𝑖 (𝑔) > 𝑀𝑖 (𝑔𝑗 )} + #{𝑔 ∈ 𝑈𝑛𝑙𝑎𝑏𝑒𝑙𝑒𝑑 | Mi(𝑔𝑗 ) > 𝑀𝑖 (𝑔)}

,

where ‘#’ denotes the cardinality of a finite set. The UPPR is the PU-learning equivalent
of the false positive rate, where lower values indicate higher confidence that a gene is
functionally associated with the AD GWAS genes. We averaged UPPR over all models
and took the negative logarithm to obtain a final functional score, FS(gj)

100

1
𝐹𝑆(𝑔𝑗 ) = − log10 (
∑ 𝑈𝑃𝑃𝑅𝑖𝑗 ) .
100
𝑖=1
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The functional score ranges from zero to infinity, with higher values indicating greater
confidence. Models were trained using the e1071 R package (Meyer et al., 2019).

Integrating functional and positional scores
To integrate functional scores for AD-specificity with imaging GWAS p-values,
we computed a novel combined score based on the empirical joint cumulative density
function (CDF) of the two scores. Specifically, every gene, g, had a functional score FS(g),
and a positional score PS(g) = -log10(pg), where pg is the MAGMA p-value for g in the
imaging GWAS. To quantify how highly ranked a gene, gj, is along both measures
simultaneously, we used the value of the empirical joint CDF as a combined score, CS(gj),

CS(g j ) =

#{g ∈ Genome| FS(g) < FS(g j ) & PS(g) < PS(g j )}
,
N

where N is the number of genes in the genome. Note that this is equivalent to the
probabilistic definition using the empirical joint distribution of the two scores. Thus, the
combined score represents the probability that a randomly chosen gene in the genome will
score lower on both measures than gj.

Functional Enrichment Analysis
To compare the functional enrichments of ADNI imaging genetics p-values versus
the combined scores, we used the g:GOSt tool in the gprofiler2 R package to identify
significantly enriched Gene Ontology terms (Kolberg et al., 2020). Specifically, we ranked
all genes by either p-value or combined score and tested the significance of all Gene
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Ontology Biological Process (GO:BP) terms (Ashburner et al., 2000; Carbon et al., 2018).
We then summarized the enriched term lists into high-level annotations using the REVIGO
online ontology analysis tool (Supek et al., 2011). Finally, we plotted high-level
annotations as pie charts using ggplot2 (Wickham, 2016).

Modularity and Gene Enrichment Analysis of Functional Networks
To visualize and interpret the outputs of our SVM predictions, we plotted subnetworks of high-ranking genes and performed enrichment analyses of network modules.
For both the hippocampal and amygdalar networks, we extracted the sub-networks of genes
with functional scores greater than two (i.e., average UPPR < 0.01). We visualized these
sub-networks using force-directed layout (Jacomy et al., 2014) in Gephi (https://gephi.org)
(Bastian et al., 2009). We identified modules in this sub-network using maximum
modularity as implemented in Gephi (Blondel et al., 2008). The list of genes in each module
was then sorted by functional score and input to g:GOSt (Raudvere et al., 2019), resulting
in significantly enriched Gene Ontology (Ashburner et al., 2000; Carbon et al., 2018),
KEGG (Kanehisa and Goto, 2000), and Reactome (Jassal et al., 2019) terms. Network
modules were annotated by manually curating a set of representative functional terms, and
the full output g:GOSt can be viewed in Supp. Files 4 and 5.

Code Availability
To ensure rigor and reproducibility of our results, all analysis code used in this study is
freely available at https://github.com/MahoneyLabGroup/AD_NBFP.
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Figure 5: Workflow overview. Each data stream, and the calculation of the integrated score, are indicated by
the bolded labels. Each section shows how data (yellow ovals) were processed by computational tools (blue
rectangles) to get results (green diamonds). Arrows indicate flow of information through the pipeline.
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Results
Hippocampal Volume, Amygdalar Volume, and AD Diagnosis Captured Distinct Genetic
Signals
The ADNI-1 dataset contains measures of hippocampal volume (HV) and
amygdalar volume (AV) of patients and controls derived from structural MRI, as well as
multiple relevant covariates: sex, age, educational attainment, and total intracranial
volume. Both of these brain volume measures correlated strongly with a patient’s clinical
cognitive status (Fig. 6A). Regional volumes were highest in control, non-AD (CN)
subjects, lower in late mild cognitive impairment (LMCI) subjects, and lowest in patients
with AD (Fig. 6A). While there was overlap between the subgroups in HV and AV, the
average size of each structure was significantly different between each clinical group (Fig.
6A), as has been previously shown in prior ADNI work (Schuff et al., 2009; Whitwell et
al., 2012).
The hippocampus and amygdala take part in overlapping limbic system neural
pathways and are physically close to one another in the temporal lobe, suggesting that
atrophy of each of these structures in AD could be highly correlated (Cavedo et al., 2011;
Wang et al., 2016b). To assess this, we corrected HV and AV for diagnosis at baseline,
intracranial volume, years of education, age, and sex using a linear model and computed
the correlation of the residuals (Fig. 6B). The residuals were significantly correlated
(R2=0.41, p=3.2e-66), indicating a significant, but moderate, correlation between the sizes
of the two structures. The moderate correlation indicates that there are likely overlapping
processes driving the size of these structures, but also biological processes that are unique
to each. It is interesting to note that, after controlling for covariates, the distributions of HV
and AV are unimodal and do not have any obvious subgroupings. Thus, for the remainder
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of the study, we treated HV and AV as quantitative traits.

Figure 6: Data processing and comparison of hippocampal and amygdalar volume GWAS and meta-GWAS
summary statistics. A) We calculated the correlation between each of the three clinical diagnoses for ADNI1 and the respective tissue volume measures. All three diagnoses showed significant (p < 2e-16) differences
in average volume size across tissues. B) Linear models predicting HV and AV were calculated to determine
the correlation in size of the two structures. There was a significant, moderate correlation (R 2 = 0.41, p =
3.6e-66) between the volumes of the two structures controlling for diagnosis at baseline, education, sex, ICV,
and age. C) Comparison of p-value distributions for the two GWAS volume measures. Dotted lines indicate
a nominal significance cutoff of 0.01. D and E) Comparison of /p/-value distributions between the metaGWAS data and the respective volume GWAS data. Genes with log transformed /p/-values greater than 20
were transformed to 20. Black dotted lines indicate a nominal significance cutoff of 0.01.

To identify genetic drivers HV and AV in patients with AD, we used PLINK 1.9
(Chang et al., 2015) to statistically associate SNPs to HV and AV, and used MAGMA
(deLeeuw et al., 2015) to integrate SNP-level association to gene-level associations (Fig.
5). Overall, three genes––APOC1, TOMM40, and APOE–– were significant after
correcting for multiple comparisons for HV, and one gene––APOC1–– was significant for
AV. Furthermore, 338 and 276 genes were nominally significant at the p=0.01 level for
HV and AV, respectively. The top-ranked genes by p-value for both HV and AV were
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APOC1, TOMM40, and APOE, which all have well-established associations to AD (Zhou
et al., 2014; Chiba-Falek et al., 2018; Zhao et al., 2018). Examining the nominally
significant genes, we found that HV and AV independently associated with a unique subset
of genes (Fig. 6C). For example, the gene GRIN2B, which plays a role in brain development
and is a candidate gene for temporal lobe epilepsy and autism spectrum disorder due to its
effects on the hippocampus (Parrish et al., 2013; Varghese et al., 2017), was nominally
significant for HV but not AV. Conversely, the gene EDN1, which is a candidate gene
antagonist for multiple system atrophy (Gu et al., 2018), was nominally significant for AV
but not HV. These results suggest that large-effect genes may have pleiotropic effects on
HV and AV, but also that separate pathways may be driving atrophy in particular
structures.
The virtue of endophenotypic measures such as HV and AV is they can potentially
resolve biologically specific components of a disease that are otherwise too convoluted
with other disease mechanisms when considering disease status alone. However, because
the ADNI data are cross-sectional, it is not clear a priori whether genetic effects on HV or
AV relate to genetic differences in brain developmental or to AD-induced atrophy. To
assess the concordance between gene associations for HV and AV associations with AD
risk per se, we compared gene-level p-values for HV and AV to corresponding p-values
from the AD meta-GWAS study recently published (Jansen et al., 2019) (Fig. 6D and E).
The Jansen et al. study is the largest AD meta-GWAS to date, and provides the most robust
data set to identify any HV- or AV-specific hit influencing AD risk. Like the comparison
between HV and AV p-values, the meta-GWAS shares several genome-wide significant
genes with HV and AV (Fig. 6D and E). Furthermore, the meta-GWAS shares some
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nominally significant genes with imaging GWAS, for example, ENAH with AV and
PICALM for HV (Fig. 6D and E). These overlapping hits, at a nominal significance level,
suggest that at least some of the variation in HV and AV is potentially driven by factors
influencing genetic AD risk.

NGR identified distinct hippocampal and amygdalar functional gene networks connecting
AD risk genes
As major components of AD pathology, genetic. risk factors for AD-induced
hippocampal and amygdalar atrophy are expected to be a subset of all AD risk factors.
However, differences in sample size (i.e., statistical power) and study population between
the case-control and imaging GWAS limit our ability to detect these overlapping
associations. Nevertheless, we expect that, beyond specific shared gene associations
between HV or AV and disease risk, risk genes for imaging endophenotypes should lie in
AD risk gene pathways. To identify the hippocampal and amygdalar pathways involved in
AD pathogenesis, we performed NGR using hippocampus- and amygdala-specific
functional genomic networks (Wong et al., 2018) to rank every gene in the genome by
how well they connect to AD-GWAS genes. Briefly, we trained an ensemble of SVM
classifiers to distinguish between AD-GWAS genes and the rest of the genome using
connection weights to AD-GWAS genes in the tissue networks as features (see Methods).
The output of this analysis was a ranked list of genes with each gene receiving a functional
score (formally, the negative logarithm of the unlabeled-predicted-positive rate) that
quantifies how well connected a gene is to AD-GWAS genes. As positive examples we
used all genes that reached a nominal level of significance (p = 0.01) in the meta-GWAS
dataset (n = 735 genes). The remaining genes were treated as unlabeled.
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To aid the interpretation of top functional hits, we visualized the sub-networks of
genes that had functional scores greater than 2 for the hippocampus and amygdala
networks. We performed modularity analysis in Gephi (Bastian et al., 2009) and identified
four modules in both sub-networks (Fig. 7). We assigned functional annotations to the
genes from each network module using g:GOSt (Raudvere et al., 2019). While the number
of modules were the same for both tissue sub-networks, the functional annotations
underscored distinct pathways. The hippocampus sub-network modules were enriched for
genes taking part in endothelial cell migration (GO:0043542), regulation of cell adhesion
(GO:0030155), Rho/RAS mediated GTPase activity (GO:0007266, GO:0046578), and
regulation of macroautophagy (GO:0016241) (Fig. 7A). The amygdala sub-network
modules were enriched for genes involved in regulation of the ERK signaling cascade and
protein ubiquitination (GO:0070372, GO:0030433), cytoskeletal and organelle
organization (GO:0051493, GO:0033043), chromatin and chromosome organization
(GO:0006325), and apoptotic signaling and cell death (GO:2001233, GO:0010941) (Fig.
7B). These enrichments covered a diverse range of processes, some of which overlapped
between tissues (e.g., regulation of macroautophagy and apoptotic signaling and cell
death), while others appeared to be tissue-specific (e.g., endothelial cell migration in the
hippocampus).
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Figure 7: Analysis of top functional subnetworks. The functional subnetwork of genes with a functional
scores greater than 2 were extracted from both tissue networks, run through a modularity algorithm, and the
modules were functionally annotated using functional enrichment analysis by g:GOSt. Several of the top hit
genes from the combined ranking appeared in a diverse array of functional classifications. Each gene is
colored by the functional module in which it is a member. Network edges were filtered to only include
weights greater than 0.25 for visual clarity. A) Amygdala sub-network analysis. The top functional subnetwork for this tissue was enriched for genes in pathways that regulate apoptosis and cell death,
cytoskeletal and organelle organization and chromosomal organization. B) Hippocampus sub-network
analysis. This top functional sub-network was enriched for genes involved in immune signaling as well as
cell adhesion and ER regulation.

Integration of functional scores with imaging GWAS p-values predicted risk genes for
AD-induced hippocampal and amygdalar atrophy
The HV and AV measurements are cross-sectional and cannot resolve whether a
genetic association is due to AD-driven atrophy or a genetically encoded difference in brain
development. Thus, the genes that associate with HV and AV need not necessarily
associate with disease status. In order to identify genes that were simultaneously associated
with HV or AV and functionally connected to AD disease risk, we computed a combined
score using the joint cumulative density function of the imaging GWAS p-values and the
functional scores from NGR. The resulting scores ranged continuously from zero to one,
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with values closer to one indicating a higher rank on both genetic and functional metrics.
Plotting the functional score vs. the negative logarithm of the imaging GWAS p-value with
a color gradient indicating each gene’s combined score, we see that some genes in the
upper-right quadrant of the point cloud scored better than 95% of the genes in the genome
on both axes (Fig. 8A and B).

Figure 8: Combined score ranking. Points are colored on a gradient by combined score with yellow points
scoring highest, and blue points scoring lowest. A) The combined score plot for the amygdala tissue. Several
of the top ranked genes were involved in the regulation gene transcription (EDF1) or the maintenance of
organelles (PRKCSH, UBE2J2) and integrity of the synapse (PAK2, ENAH). B) The combined score plot for
the hippocampus tissue. Several genes were involved in processes required for the maintenance of the
synapse (PFN1, IQSEC1) regulation of gene transcription (HDAC3) and proper ER regulation (PRKCSH,
MOGS).
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The purpose of the combined score was to prioritize AD-specific genes and
distinguish them from genes influencing HV and AV through developmental pathways. To
establish a specific enrichment for AD-relevant pathways, we compared functional
enrichments between ranking genes by p-value (ascending) and by combined score
(descending). To summarize the large lists of enriched terms, we used REVIGO to
compress the enrichments into representative high-level terms (Supek et al., 2011). For the
hippocampus and amygdala (Fig. 9), the p-value analyses revealed an enrichment for genes
involved in cholesterol metabolism and cell adhesion. On the other hand, the combined
score in the hippocampus was enriched for terms involved in the regulation of the immune
response and cellular stress related to the endoplasmic reticulum (ER). Similarly, for the
amygdala, the combined score was enriched for pathways involved in ER stress and neuron
growth. These results demonstrate that the combined score prioritizes genes involved in
AD-relevant functional pathways, distinct from those regulated by APOE (e.g., cholesterol
metabolism) (Schliebs and Arendt, 2011; Heneka et al., 2015; Gerakis and Hetz, 2018).
Notably, while the combined score ranked genes involved in AD-relevant pathways
highly, many of the top-10 genes have not been previously annotated to the disease (Table
1 and 2). High-scoring hippocampal genes are involved in actin regulation (PFN1,
IQSEC1, PAK2), protein regulation in the ER (MOGS and PRKCSH), and transcriptional
regulation (HDAC3). Highly ranked genes in the amygdala are involved in a wide range of
processes. including regulation of proteins in the ER (PRKCSH and UBE2J2), transcription
modification or cell cycle modulation (KAT5, EDF1, and ZNHIT1), and the maintenance
and development of healthy synapses (SRGAP1 and PAK2). The top 10 genes in both the
hippocampus and amygdala were distributed throughout the NGR functional networks and
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were present in all functional modules (Fig. 7).

Figure 9: Functional enrichment analysis using p-value and combined score. A) Functional enrichment
analysis of amygdala volume GWAS p-value ranking and combined score rankings. The p-value functional
enrichment analysis revealed terms like biological cell adhesion and macromolecular complex remodeling.
By comparison, the functional enrichment analysis for the combined score revealed terms relating to ER
stress, neuron projection development, and response to oxygen levels which are all pathways affected by AD
pathophysiology. B) Functional enrichment analysis of hippocampal volume GWAS p-value ranking and
combined score rankings. The p-value functional enrichment analysis saw similar enrichments as the
amygdala p-value functional enrichment analysis. The combined score functional enrichment analysis on the
other hand, saw enrichment of pathways involved in development, ER stress, and immune response
regulation.
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Discussion
As a complex disease, the genetic risk for AD is distributed over a wide variety of
cellular and molecular pathways. Thus, the genetic architecture of AD is expected to be
dominated by thousands of small-effect variants that each slightly perturb brain physiology
toward a more AD-susceptible state, rather than a small set of highly penetrant mutations.
Indeed, even the well-studied APOE-E4 risk allele has an odds ratio of only 11.8 in the
Caucasian population, which is by no means a certainty for any carrier (Jia et al., 2020).
The value of genetic network analysis to the study of the architecture of complex disease,
therefore, is to aggregate these many small perturbations into a pathway- and process-level
description of the full disease. To this end, our results clearly implicate common mutations
in many genes as perturbations of pathways that react to the aberrant accumulation of Aβ
in the brain (Fig. 10; discussed below). Far from being statistical noise, genes with
nominally significant p-value from the imaging GWAS are enriched for AD-specific
biology. Interestingly, the gene-level p-values largely did not replicate between imaging
GWAS and the case-control meta-GWAS. It was only after identifying the relevant tissuespecific functional sub-networks with NGR that we could resolve the likely AD-specific
genes for HV and AV. Validating any of these high-ranking genes as specifically
influencing hippocampal or amygdalar atrophy is beyond the scope of this study, but many
top hits have strong connections to well-established AD biology.
The pathognomonic signature of AD is the aggregation of amyloid β (Aβ) peptide
into amyloid plaques in the brain. Beyond aggregating into plaques, however, Aβ is
associated with a number of pathological processes, including loss of synaptic integrity
(Rönicke et al., 2011; Parsons and Raymond, 2014; Wang and Reddy, 2016; Singh et al.,
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2017; Kang and Woo, 2019; Schaeverbeke et al., 2019) and dysregulating neuronal and
astrocytic calcium channels (Yu et al., 2005; Rönicke et al., 2011; Parsons and Raymond,
2014; Lim et al., 2016; Wang and Reddy, 2016; Verkhratsky et al., 2017; Liu et al., 2019).
At the astrocyte, Aβ has been shown to bind Alpha-7 nicotinic acetylcholine receptors (ɑ7
nAChRs), causing an influx of calcium to the astrocyte and glutamate release into the
synapse (Pirttimaki et al., 2013). At the synapse, Aβ has been shown to bind to N-methylD-aspartate receptors (NMDARs) preventing glutamate from activating the channel to
allow an influx of calcium ions (Liu et al., 2019). Loss of current through NMDARs drives
depression of synaptic strength at that synapse, as lower levels of calcium initially drive
the endocytosis of α-amino-3-hydroxy-5-methyl-4-isoxasolepropionic acid receptors
(AMPARs) and later NMDARs in the postsynaptic neuron (Tigaret et al., 2006; Yu et al.,
2010). Loss of synaptic efficacy is a critical signal for synaptic pruning (Lüscher and
Malenka, 2012), and an accumulated loss of synapses is one possible mechanism for loss
of network function. Beyond synaptic pruning, Aβ is associated with a loss of synaptic
integrity, where the neurotransmitters, such as glutamate, can leak out of the synapse and
activate extra-synaptic receptors (Hardingham and Bading, 2010; Parsons and Raymond,
2014). It has been hypothesized that the high level of glutamate release by astrocytes leads
to an increase in extra-synaptic glutamate signaling and excitotoxicity (Sattler et al., 2000;
Hardingham and Bading, 2010; Parsons and Raymond, 2014; Wang and Reddy, 2016),
which is hypothesized to both induce ER stress (Sokka et al., 2007; Concannon et al., 2008)
and activate pro-apoptotic pathways (Hardingham et al., 2002), while antagonizing prosurvival pathways, particularly brain-derived neurotrophic factor (BDNF) signaling,
leading to neuron death (Hardingham et al., 2002; Hardingham and Bading, 2010; Parsons
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and Raymond, 2014; Wang and Reddy, 2016). Thus, the accumulation of Aβ acts through
multiple complex pathways––at the synapse, at the ER, and through transcriptional
regulation––to cause atrophy of neural tissue. Importantly, our top-ranking genes in both
the hippocampus and the amygdala act in these Aβ-response pathways.
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Table 1: Brief descriptions of the top genes according to the combined score for the hippocampus. Genes in
bold have been previously found in AD GWAS. PMIDs from supporting papers are included in parentheses
under bolded gene names.

Gene

PFN1

HDAC3

PRKCSH

Functional Score

0.00148

0.00549

0.00249

p-value

Role (with PMID)

1.56E-03

Increased actin depolymerization
in hippocampus of APP/PS1 mice
indicates impaired synaptic
plasticity (PMID: 31472195).
Actin remodeling mediated by
SGK1, a gene involved in spatial
memory formation and
consolidation (PMID: 31981651).
Critical for proper PNS
myelination, organization, and
development (PMID: 24598164).

2.44E-03

Nuclear HDAC3 is significantly
increased in the hippocampus of
6- and 9-month-old APP/PS1
mice compared with age-matched
wild-type C57BL/6 mice.
Inhibition of HDAC3 in the
hippocampus attenuated spatial
memory deficits, and decreased
amyloid plaque load and ABeta
levels. Dendiritic spine density
increased while microglial
activation alleviated after
HDAC3 inhibition. Over
expression led to an increase in
hipppocampal feels of Abeta,
activation of microglia, and
decreased dendritic spine density
(PMID: 28771976).

6.06E-03

Colocalizes with IP3Rs which
mediate calcium release from the
ER, specifically in hippocampal
neurons. Additionally, PRKCSH
enhances IP3-induced calcium
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release and has been found to
regulate ATP-induced CA2+
(PMID: 18990696).

APOE
(29107063)

MOGS

NECTIN2
(29107063)

PICALM
(19734902)

0.0130

0.00581

0.0141

0.0109

1.78E-12

Lipid transporter that binds to
cell-surface receptors to aid in
cholesterol transport and
membrane homeostasis. It is
present in a broad range of
functional pathways within the
CNS including synaptic plasticity,
mitochondrial function, and
neuroinflammation. Its epsilon 4
allele is one of the biggest risk
factors for AD (PMID:
28434655).

7.21E-03

Located in the lumen of the ER
where it performs N-linked
glycosylation. Several mutations
within the gene can lead to
congenital diseases of
glycosylation which can lead to
major structural malformations
within the brain, liver, lungs, and
many other higher-order tissues
and organs (PMID: 30587846).

8.12E-07

Also known as PVRL2, this gene
is a component protein of
adherens junctions between cells.
Has wide ranging roles in cell
signaling to natural killer cells to
leukocyte transport in endothelial
cells (PMID: 28062492).

3.52E-03

Involved in clathrin assembly.
Two SNPs 5’ to the gene are
associated with Reduced LOAD
Risk (PMID: 19734902;
24162737; 19734903), but their
functions have not yet been
determined. It colocalizes with
APP and over-expression of
PICALM in vivo increases plaque
deposition in AD transgenic mice
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(PMID: 22539346). Binds to
autophagosomes, suggesting a
role in autophagy mediated Abeta
clearance (PMID: 24067654).

NACC2

IQSEC1

CYB561

0.0139

0.00974

0.00496

5.19E-04

Transcription repressor within the
p53 pathway: inhibits the
expression of MDM2 which
stabilizes the expression of p53
an important tumor suppressor
(PMID: 22926524).

6.14E-03

Loss of function affects a wide
variety of actin-dependent
cellular processes, including
AMPA and NMDA receptor
trafficking at synapses (PMID:
20547133). Mutations have led to
intellectual disability and
developmental delays in those
affected (PMID: 31607425).

1.24E-02

An electron transporter critical for
the conversion of dopamine to
epinephrine and norepinephrine.
A mutation in this gene, which
disrupts the final production of
norepinephrine, has been
observed in families with severe
orthostatic hypotension (PMID:
29343526).
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Multiple high-ranking genes influence synaptic structure through the cytoskeleton
Altered synaptic structure and function are well-established in AD (Spires-Jones
and Knafo, 2012; Pozueta et al., 2013; Chabrier et al., 2014; Price et al., 2014; Mango et
al., 2019; Koller and Chakrabarty, 2020). The highest-ranking hippocampal gene, PFN1
(Fig. 10A; Table 1), encodes an actin-monomer binding protein that is known to regulate
the cytoskeleton of neurites (Murk et al., 2012), but has also been shown to support the
highly mobile F-actin in astrocytic projections that surround synaptic clefts (Schweinhuber
et al., 2015). It has been associated with impaired synaptic plasticity and spatial memory
in the APP/PS1 mouse model of AD (Sun et al., 2019; Lian et al., 2020). Alterations to the
function of PFN1 due to AD risk mutations could account for alterations in synaptic
maintenance, leading to increased glutamate signaling to extra-synaptic NMDARs. PFN1
activity is promoted by BDNF, which is hypothesized to be inhibited by extrasynaptic
glutamate signaling, and loss of that signal could stop proper formation of actin at neurite
outgrowths and potentially in astrocytic processes supporting synaptic clefts (Murk et al.,
2012; Parsons and Raymond, 2014; Schweinhuber et al., 2015).
Another high-ranking hippocampal gene was IQSEC1 (also known as BRAG2),
which encodes a guanine nucleotide exchange factor, ARF-GEF100, that is critical for the
proper maintenance of excitatory synapses through AMPA and NMDA receptor
trafficking, and regulating synaptic long-term depression (Ottis et al., 2013; Elagabani et
al., 2016; Um, 2017; Ansar et al., 2019) (Fig. 10B, Table 1). Loss of function mutations in
IQSEC1 have been associated with intellectual disability (Elagabani et al., 2016) and a
biallelic variant mutation has been observed in two families exhibiting intellectual
disability and developmental delays (Ansar et al., 2019). A recent study in Wistar rats
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found that BRAG2 is a member of a small network of proteins that are dysregulated in
response to age-induced changes in proteostasis (Ottis et al., 2013). Significantly, changes
in this protein network led to impaired learning and memory performance (Ottis et al.,
2013). Thus, common variants in IQSEC1 could play a role in synaptic reorganization in
response to aging and Aβ burden in AD.
The highest scoring amygdala gene was PAK2, which supports actin formation and
the promotion of dendritic spine formation (Bokoch, 2003; Shin et al., 2009; Wang et al.,
2018) (Fig. 10C, Table 2). Mutations in PAK2 are associated with other neurological
disorders, including autism spectrum disorder and a 3q29 microdeletion syndrome with a
range of neurological phenotypes including intellectual disability and autism (Wang et al.,
2018). PAK family proteins have been associated with impaired dendritic spine formation
in in vitro AD models (Ma et al., 2008), and PAK2 has been shown to be cleaved by caspase
resulting in cell death (Marlin et al., 2011). Recent work has also shown that LIMK1, a
downstream signaling molecule from PAK2, is involved in a ROCK2 actin regulatory
pathway which mediates Aβ42-induced spine degeneration as well as neuronal
hyperexcitability in hAPP mice (Henderson et al., 2019). PAK2 activity is regulated by the
Slit/roundabout (ROBO) signaling pathway (Dubrac et al., 2016; Xu et al., 2018), which
is primarily involved in modulating axonal guidance and neuronal migration (Dickson and
Gilestro, 2006; Mastick et al., 2010; Slováková et al., 2012), via the CDC42 GTPase
(Wong et al., 2001; Xu et al., 2018; Huang et al., 2020). Another high-ranking amygdala
gene, SRGAP1, suppresses the activity of PAK2 through the Slit/ROBO signaling pathway
(Dubrac et al., 2016; Xu et al., 2018) (Fig 6C, Table 2). Slit binds to ROBO and activates
the SRGAP1 protein which triggers the hydrolysis of GTP by the CDC42 GTPase, which
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attenuates PAK2 activity (Dubrac et al., 2016; Feng et al., 2016). Thus, common variants
that modify the activity of PAK2 or its upstream regulator, SRGAP1, could lead to
alterations in synaptic morphology and axonal migration, and possibly to cleaved PAK2
signaling for neuronal death.
A final cytoskeletal protein among the top-rankings genes was ENAH in the
amygdala. The ENAH protein has been found to form a complex with Fe65, a
transcriptional activator and protein involved in neurite outgrowth and binding partner of
amyloid precursor protein (APP) (Sabo et al., 2001; Li et al., 2018) (Fig 6D, Table 2).
ENAH also binds to ROBO and profilin (PFN), acting as an inhibitor of motility and
regulator of actin dynamics, respectively (Gertler et al., 1996; Lanier et al., 1999; Bear et
al., 2000; Lanier and Gertler, 2000). Greater association of ENAH with the Fe65-APP
complex supports neurite outgrowth and motility, whereas binding to ROBO inhibits that
activity (Sabo et al., 2001). Common variants in ENAH, therefore, could influence synaptic
plasticity through its association with the major AD risk factor APP (Trillaud-Doppia and
Boehm, 2018).
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Table 2: Brief descriptions of the top genes according to the combined score for the amygdala. Genes in
bold have been previously found in AD GWAS. PMIDs from supporting papers are included in parentheses
under bolded gene names.

Gene

Functional Score p-value

PRKCSH

0.0293

1.13E-03

TOMM40
(29107063)

0.00626

2.66E-11

PAK2

0.00508

9.50E-04

SRGAP1

0.00308

2.89E-03

UBE2J2

0.00771

2.88E-04
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Role (with PMID
Colocalizes with IP3Rs which
mediate calcium release from the
ER, specifically in hippocampal
neurons. Additionally, PRKCSH
enhances IP3-induced calcium
release and has been found to
regulate ATP-induced CA2+
(PMID: 18990696).
Mitochondrial membrane protein
critical for transport of protein
precursors into the mitochondria
and is associated with
mitochondrial dysfunction in AD.
Further, it has recently been found
to be associated with functional
connectivity of brain regions via
fMRI (PMID: 31568198). It is in
LD with APOE.
Haploinsufficiency of PAK2 has
been observed to decrease synapse
density, impair LTP, and drive
autism related behaviors in mice
(PMID: 30134165). Strong
regulator of cellular senescence
and organismal aging through
gene-expression and the H3.3
nucleosome assembly (PMID:
31209047).
A GTPase activator that works
with CDC42 to negatively regulate
neuronal migration. Interacts with
ROBO1 to inactivate CDC42.
(PMID: 11672528)
Ubiquitination by this protein is a
potential mechanism for
endoplasmic reticulum-associated
depredation (ERAD) (PMID:

KAT5

0.00459

4.31E-03

EDF1

0.00181

8.50E-03

ENAH

0.00740

6.99E-03

ZNHIT1

0.00368

1.63E-02

APOE
(29107063)

0.0162

7.00E-11
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19951915; 25083800).
A histone acetyl transferase (HAT)
that plays a role in DNA repair and
apoptosis as well as signal
transduction. Complexes with the
intracellular domain of the cleaved
APP products to form nuclear
spheres which seem to have a role
in cell-cycle regulation, but are not
well understood (PMID:
27644079).
Transcriptional regulator of PPARgamma which has a wide array of
roles in combatting AD
pathophysiology including
amyloid clearance and metabolic
regulation (PMID: 22109891,
24838579).
Complexes with FE65 and that
association may have an effect on
APP biogenesis (PMID: 9407065).
Also involved in actin
polymerization and cell motility
(PMID: 10069337, 10892743).
Induces arrest of cell cycle at G1
and CDK6 was strongly downregulated by Znhit1 through
transcriptional repression (PMID:
19501046). CDK6 is unregulated
in patients in AD compared to nonAD controls (PMID: 26766955).
Lipid transporter that binds to cellsurface receptors to aid in
cholesterol transport and
membrane homeostasis. It is
present in a broad range of
functional pathways within the
CNS including synaptic plasticity,
mitochondrial function, and
neuroinflammation. Its epsilon 4
allele is one of the biggest risk
factors for AD (PMID: 28434655).

PRKCSH potentially regulates excitotoxicity in AD
Loss of synaptic integrity coupled with impaired glutamate clearance by astrocytes
caused by Aβ leads to high levels of extracellular glutamate, which binds to NMDARs
increasing intracellular calcium levels (Parsons and Raymond, 2014; Liu et al., 2019).
Under physiological conditions, the ER and other organelles act as calcium sinks that
modulate intracellular ion levels.
Excitotoxicity occurs when intracellular calcium levels exceed the buffering
capacity of the cell. The only top-ten gene shared by both tissues, aside from APOE, was
PRKCSH (Tables 1 and 2), which encodes the protein kinase C substrate 80K-H (80K-H),
a glucosidase enzyme in the ER. 80K-H is known to colocalize with the inositol
triphosphate receptor (IP3R), an ER-resident calcium channel that facilitates calcium
currents in the ER (Kawaai et al., 2009) (Fig. 10E). Common variants in PRKCSH could
modify neuronal responses to excitotoxic levels of calcium, potentially exacerbating tissue
atrophy in the hippocampus and amygdala.

ER stress and misfolded protein response genes could contribute to apoptotic signaling
Several other high-ranking genes are integral to the proper folding of proteins in
the ER. ER stress occurs when the ability of the ER to properly fold proteins becomes
saturated (Lin et al., 2007). The hippocampal gene MOGS encodes a glycosylation enzyme
that aids in protein folding (Sadat et al., 2014; Li et al., 2019) (Fig. 10F, Table 1). Common
variants in MOGS could modify the rate at which ER stress occurs and exacerbate ADrelated hippocampal atrophy.
When the ER reaches a critical state of misfolded proteins, ER-associated
degradation (ERAD) can be triggered. ERAD is a process by which misfolded proteins are
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ubiquitinated and then proteolyzed to prevent the misfolded polymers from causing cellular
damage. The amygdalar gene UBE2J2 encodes a ubiquitin conjugating enzyme that marks
misfolded proteins for degradation (Wang et al., 2009b; Glaeser et al., 2018) (Fig. 10F,
Table 2). In some cases, ERAD can be triggered as part of apoptosis, and ubiquitination
enzymes, including UBE2J2, are recruited to ubiquitinate misfolded proteins (Glaeser et
al., 2018). Common variants in UBE2J2 could affect the misfolded protein response and
exacerbate cellular damage due to misfolded proteins.

High ranking transcriptional regulators could have pleiotropic effects on AD
A final set of high-ranking genes was broadly involved in transcriptional regulation.
The high-ranking amygdala gene EDF1 encodes a factor that acts as a transcriptional
coactivator of peroxisome proliferator-activated receptor-gamma (PPARγ) (Fig. 10G,
Table 2). PPARγ has multiple functions, including regulating metabolism (Pipatpiboon et
al., 2012), supporting vascular endothelial cells (Cazzaniga et al., 2018), and promoting
BDNF expression (d’Angelo et al., 2019). It has been hypothesized that PPARγ counteracts
insulin resistance and metabolic dysfunction in AD (HOYER and LANNERT, 1999;
Pipatpiboon et al., 2012). It potentially also plays a role in modifying extracellular Aβ
levels by facilitating increased uptake of Aβ by neurons and glia (Mandrekar-Colucci et
al., 2012). PPARγ also downregulates the pro-inflammatory mechanisms of AD pathology
(Combs et al., 2000; Govindarajulu et al., 2018). Common variants within the EDF1 gene
could have pleiotropic effects on cellular function through the regulation of PPARγ.
The hippocampal gene HDAC3 encodes a histone deacetylase enzyme that
epigenetically regulates gene expression (McQuown and Wood, 2011; Nott et al., 2016)
(Fig. 10H, Table 1). Extra-synaptic glutamate signaling drives pro-apoptotic gene
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expression, in part through the FOXO transcription factor, which is upregulated by extrasynaptic signaling (Parsons and Raymond, 2014). FOXO forms a complex with HDAC3,
the protein product of HDAC3, and suppresses gene transcription (Nott et al., 2016). Thus,
common variants in HDAC3 could influence pro-apoptotic gene expression, exacerbating
hippocampal atrophy.
HDAC3, and other members of the HDAC family, also negatively regulate longterm memory formation (McQuown and Wood, 2011; Zhu et al., 2017), via the “molecular
brake pad hypothesis” (McQuown and Wood, 2011). The molecular brake pad hypothesis
posits that the tight binding of HDACs to the promoters of genes that drive memory
formation requires high-levels of activity-dependent signaling to dissociate them and
enable protein synthesis-dependent long-term memory formation (McQuown and Wood,
2011). Notably, HDAC3 has also been found to affect dendritic spine density, amyloid
burden, microglial activation, and spatial memory in the APP/PS1 AD mouse model (Zhu
et al., 2017). Furthermore, in the 3xTG-AD mouse model, inhibition of HDAC3 reversed
AD-related pathologies (Janczura et al., 2018), and in cultured rat hippocampal neurons,
inhibition of HDAC3 reversed Aβ-induced plasticity deficits (Krishna et al., 2016).
Interestingly, another histone deacetylase inhibitor, HDAC2, is emerging as a potential
drug target in AD (Choubey and Jeyakanthan, 2018). Together, these results suggest
pleiotropic roles for HDAC3 as a gene influencing hippocampal atrophy in AD.

In summary, the genes prioritized by our integrative method are robustly related to
AD by prior research and have clear pathways connecting them to neuron death, and
therefore, to the imaging signals of low HV and AV.
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Figure 10: Illustration of neuronal and astrocytic pathways implicated in the disease according to the top
scoring genes according to our integrated ranking. A) Loss of signal from BDNF to PFN1 downregulates the
activity of the gene, impairing F-actin structure in the neuron and astrocyte. B) IQSEC1 mediates AMPAR
and NMDAR receptor internalization. C) PAK2 activity is partially regulated by the CDC42 GTPase which
is activated by binding of the SLIT protein to ROBO at the membrane. This activity can be interrupted by
the activity of SRGAP1 which inhibits ROBO signaling. D) ENAH can bind to both ROBO and Fe65. When
bound to ROBO it acts to inhibit actin polymerization and motility, but while bound to Fe65 and the AICD
the ROBO pathway functions normally, promoting cell motility and actin polymerization. E) PRKCSH colocalizes with IP3Rs increasing calcium current through the channels, increasing cytosolic levels of Ca 2+. F)
UBE2J2 and MOGS are both involved in the proper regulation of intra-ER processes. Impairment of the
proper activity of post-translational modification by MOGS could drive ERAD mediated by ubiquitination
by UBE2J2. G) EDF1 is also a transcriptional regulator for PPAR-gamma. Activation of PPAR-gamma helps
to regulate disturbed metabolic states and A plaque clearance. H) HDAC3 regulates transcription of many
genes that have an effect on A burden, microglial activation, and dendritic spine density.
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The present study was potentially limited by a number of important factors. First,
by treating HV and AV independently as quantitative traits, we potentially miss important
population substructure (e.g., discrete patient subgroups with extreme neuropathology).
While we do not see obvious subgroups in the HV/AV data (Fig. 10), it is possible that by
paring MRI with other phenotypic measures, such groups could appear. Future multi-trait
analyses could have greater power to detect risk factors for patient subgroups, such as those
that have been detected in gene expression data (Mukherjee et al., 2020). In particular, with
emerging longitudinal data, it may become possible to identify subgroups that have distinct
disease trajectories. Second, we have applied an NGR method that has been extensively
tested, applied, and validated (Guan et al., 2010; Gorenshteyn et al., 2015; Goya et al.,
2015; Greene et al., 2015; Krishnan et al., 2016; Song et al., 2016; Yao et al., 2018; Tyler
et al., 2019). However, NGR methods are under active development, with new variants
using different machine learning strategies or molecular networks. Future work can
benchmark different NGR strategies prior to our integrative prioritization to identify the
most robust combination of molecular network and learning algorithm for AD GWAS.
Third, the present study focused on the genomic data alone. Neither the meta-GWAS or
the ADNI-1 data in this study have gene expression for the study participants. However,
gene expression data from patients with AD exist in other data sets, such as the Religious
Orders Study (Bennett et al., 2012). Future work could integrate gene expression data into
a prioritization pipeline, which has been done in other fields, such as cancer (Ritchie et al.,
2013). Finally, we have not validated any of our gene candidates experimentally, and the
proposed mechanisms for our highly ranked genes are speculative.
Despite the above limitations, however, the integrative approach we have taken has
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strongly implicated cytoskeletal dynamics, ER stress, and transcriptional dysregulation as
major cellular processes driving neural atrophy. While it is beyond the scope of the present
study to validate any of our candidates, by highlighting specific cellular processes and
genes taking part in those processes, we can design robust in vivo and in vitro experiments
to test them. For example, recent results in cultured neurons implicate impaired dendritic
dynamics as a hallmark of AD (Froula et al., 2018; Boros et al., 2019; Henderson et al.,
2019; Walker and Herskowitz, 2020; Walker et al., 2021). (Froula et al., 2018; Boros et
al., 2019; Henderson et al., 2019; Walker and Herskowitz, 2020; Walker et al., 2021). Such
culture systems could be used for follow up experiments in which our candidate genes
could feasibly be tested at scale.

81

Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or
financial relationships that could be construed as a potential conflict of interest.

Author Contributions
JLB and JMM designed the study. JLB obtained the data and analyzed it using the pipeline
designed by ALT and JMM. JLB, MKL, ALT, and JMM drafted and revised this
manuscript. All authors contributed to the article and approved the submitted version.

Funding
This work was supported by the National Library of Medicine (5R21LM012615-02) and
the National Institute of General Medical Sciences (5P20GM130454-02).

Acknowledgements
Data collection and sharing for this project was funded by the Alzheimer's
Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01
AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-20012). ADNI is funded by the National Institute on Aging, the National Institute of
Biomedical Imaging and Bioengineering, and through generous contributions from the
following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation;
Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir,
Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company;
EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.;
Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research &
Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development
82

LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx
Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.;
Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition
Therapeutics. The Canadian Institutes of Health Research is providing funds to support
ADNI clinical sites in Canada. Private sector contributions are facilitated by the
Foundation for the National Institutes of Health (www.fnih.org). The grantee
organization is the Northern California Institute for Research and Education, and the
study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University
of Southern California. ADNI data are disseminated by the Laboratory for Neuro
Imaging at the University of Southern California.

Data Availability Statement
The gene level summary statistics along with the pipeline used to generate the data will
be provided in our GitHub repository upon publication.

83

References

Andrews, S. J., Fulton-Howard, B., and Goate, A. (2020). Interpretation of risk loci from
genome-wide association studies of Alzheimer’s disease. Lancet Neurology 19, 326–
335. doi:10.1016/s1474-4422(19)30435-1.
Ansar, M., L., C., H., A., A.-O., N., E., M., A., R., T., A., P., S., et al. (2019). Bi-allelic
Variants in IQSEC1 Cause Intellectual Disability, Developmental Delay, and Short
Stature. Am J Hum Genetics 105, 907–920. doi:10.1016/j.ajhg.2019.09.013.
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., et al.
(2000). Gene Ontology: tool for the unification of biology. Nat Genet 25, 25–29.
doi:10.1038/75556.
Barrett, T., E., W., S., P., L., C., E., F., K., I., M., T., et al. (2013). NCBI GEO: archive
for functional genomics data sets--update. Nucleic Acids Res 41, D991-5.
doi:10.1093/nar/gks1193.
Bastian, M., Heymann, S., and Jacomy, M. (2009). Gephi: An Open Source Software for
Exploring and Manipulating Networks. doi:10.13140/2.1.1341.1520.
Bear, J. E., Loureiro, J. J., Libova, I., Fässler, R., Wehland, J., and Gertler, F. B. (2000).
Negative Regulation of Fibroblast Motility by Ena/VASP Proteins. Cell 101, 717–728.
doi:10.1016/s0092-8674(00)80884-3.
Bennett, D. A., A., S., J., Z., A., and S., W., R. (2012). Overview and findings from the
religious orders study. Curr Alzheimer Res 9, 628–45.
doi:10.2174/156720512801322573.
Bhagwat, N., Viviano, J. D., Voineskos, A. N., Chakravarty, M. M., and Initiative, A. D.
N. (2018). Modeling and prediction of clinical symptom trajectories in Alzheimer’s
disease using longitudinal data. Plos Comput Biol 14, e1006376.
doi:10.1371/journal.pcbi.1006376.
Blondel, V. D., Guillaume, J.-L., Lambiotte, R., and Lefebvre, E. (2008). Fast unfolding
of communities in large networks. Arxiv. doi:10.1088/1742-5468/2008/10/p10008.
Bokoch, G. M. (2003). BIOLOGY OF THE P21-ACTIVATED KINASES. Annu Rev
Biochem 72, 743–781. doi:10.1146/annurev.biochem.72.121801.161742.
Boros, B. D., Greathouse, K. M., Gearing, M., and Herskowitz, J. H. (2019). Dendritic
spine remodeling accompanies Alzheimer’s disease pathology and genetic
susceptibility in cognitively normal aging. Neurobiol Aging 73, 92–103.
doi:10.1016/j.neurobiolaging.2018.09.003.
84

Browning, B. L., Zhou, Y., and R., B., S. (2018). A One-Penny Imputed Genome from
Next-Generation Reference Panels. Am J Hum Genetics 103, 338–348.
doi:10.1016/j.ajhg.2018.07.015.
Calderon-Garcidueñas, A. L., and Duyckaerts, C. (2017). Chapter 23 Alzheimer disease.
Handb Clin Neurology 145, 325–337. doi:10.1016/b978-0-12-802395-2.00023-7.
Carbon, S., Douglass, E., Dunn, N., Good, B., Harris, N. L., Lewis, S. E., et al. (2018).
The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res 47,
gky1055-. doi:10.1093/nar/gky1055.
Carmona, S., Hardy, J., and Guerreiro, R. (2018). Chapter 26 The genetic landscape of
Alzheimer disease. Handb Clin Neurology 148, 395–408. doi:10.1016/b978-0-44464076-5.00026-0.
Cavedo, E., Boccardi, M., Ganzola, R., Canu, E., Beltramello, A., Caltagirone, C., et al.
(2011). Local amygdala structural differences with 3T MRI in patients with Alzheimer
disease. Neurology 76, 727–733. doi:10.1212/wnl.0b013e31820d62d9.
Cazzaniga, A., Locatelli, L., Castiglioni, S., and Maier, J. (2018). The Contribution of
EDF1 to PPARγ Transcriptional Activation in VEGF-Treated Human Endothelial
Cells. Int J Mol Sci 19, 1830. doi:10.3390/ijms19071830.
Chabrier, M. A., Cheng, D., Castello, N. A., Green, K. N., and LaFerla, F. M. (2014).
Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in
a floxed double transgenic model of Alzheimer’s disease. Neurobiol Dis 64, 107–117.
doi:10.1016/j.nbd.2014.01.007.
Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., and Lee, J. J.
(2015). Second-generation PLINK: rising to the challenge of larger and richer
datasets. Gigascience 4, 1–16. doi:10.1186/s13742-015-0047-8.
Chiba-Falek, O., Gottschalk, W. K., and Lutz, M. W. (2018). The effects of the
TOMM40 poly-T alleles on Alzheimer’s disease phenotypes. Alzheimer’s Dementia
14, 692–698. doi:10.1016/j.jalz.2018.01.015.
Choubey, S. K., and Jeyakanthan, J. (2018). Molecular dynamics and quantum chemistrybased approaches to identify isoform selective HDAC2 inhibitor – a novel target to
prevent Alzheimer’s disease. J Recept Sig Transd 38, 1–13.
doi:10.1080/10799893.2018.1476541.
Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., and Landreth, G. E. (2000).
Inflammatory Mechanisms in Alzheimer’s Disease: Inhibition of β-AmyloidStimulated Proinflammatory Responses and Neurotoxicity by PPARγ Agonists. J
Neurosci 20, 558–567. doi:10.1523/jneurosci.20-02-00558.2000.
85

Concannon, C. G., Ward, M. W., Bonner, H. P., Kuroki, K., Tuffy, L. P., Bonner, C. T.,
et al. (2008). NMDA receptor‐mediated excitotoxic neuronal apoptosis in vitro and in
vivo occurs in an ER stress and PUMA independent manner. J Neurochem 105, 891–
903. doi:10.1111/j.1471-4159.2007.05187.x.
Consortium, 1000 Genomes Project, A., A., D., B., L., M., D., R., P., G., E., M., K., H., et
al. (2015). A global reference for human genetic variation. Nature 526, 68–74.
doi:10.1038/nature15393.
d’Angelo, M., Castelli, V., Catanesi, M., Antonosante, A., Dominguez-Benot, R.,
Ippoliti, R., et al. (2019). PPARγ and Cognitive Performance. Int J Mol Sci 20, 5068.
doi:10.3390/ijms20205068.
Dickson, B. J., and Gilestro, G. F. (2006). Regulation of Commissural Axon Pathfinding
by Slit and its Robo Receptors. Cell Dev Biology 22, 651–675.
doi:10.1146/annurev.cellbio.21.090704.151234.
Dubrac, A., Genet, G., Ola, R., Zhang, F., Pibouin-Fragner, L., Han, J., et al. (2016).
Targeting NCK-Mediated Endothelial Cell Front-Rear Polarity Inhibits
Neovascularization. Circulation 133, 409–421.
doi:10.1161/circulationaha.115.017537.
Elagabani, M. N., D., B., M., K., J., P., G., K., D., S., et al. (2016). Subunit-selective NMethyl-d-aspartate (NMDA) Receptor Signaling through Brefeldin A-resistant Arf
Guanine Nucleotide Exchange Factors BRAG1 and BRAG2 during Synapse
Maturation. J Biol Chem 291, 9105–18. doi:10.1074/jbc.m115.691717.
Elkan, C., and Noto, K. (2008). Learning classifiers from only positive and unlabeled
data. undefined, 213–220. doi:10.1145/1401890.1401920.
Feng, Y., Feng, L., Yu, D., Zou, J., and Huang, Z. (2016). srGAP1 mediates the
migration inhibition effect of Slit2-Robo1 in colorectal cancer. J Exp Clin Canc Res
35, 191. doi:10.1186/s13046-016-0469-x.
Froula, J. M., Henderson, B. W., Gonzalez, J. C., Vaden, J. H., Mclean, J. W., Wu, Y., et
al. (2018). α-Synuclein fibril-induced paradoxical structural and functional defects in
hippocampal neurons. Acta Neuropathologica Commun 6, 35. doi:10.1186/s40478018-0537-x.
Gerakis, Y., and Hetz, C. (2018). Emerging roles of ER stress in the etiology and
pathogenesis of Alzheimer’s disease. Febs J 285, 995–1011. doi:10.1111/febs.14332.
Gertler, F. B., Niebuhr, K., Reinhard, M., Wehland, J., and Soriano, P. (1996). Mena, a
Relative of VASP and Drosophila Enabled, Is Implicated in the Control of
Microfilament Dynamics. Cell 87, 227–239. doi:10.1016/s0092-8674(00)81341-0.
86

Glaeser, K., Urban, M., Fenech, E., Voloshanenko, O., Kranz, D., Lari, F., et al. (2018).
ERAD‐dependent control of the Wnt secretory factor Evi. Embo J 37.
doi:10.15252/embj.201797311.
Gorenshteyn, D., Zaslavsky, E., Fribourg, M., Park, C. Y., Wong, A. K., Tadych, A., et
al. (2015). Interactive Big Data Resource to Elucidate Human Immune Pathways and
Diseases. Immunity 43, 605–614. doi:10.1016/j.immuni.2015.08.014.
Govindarajulu, M., Pinky, P. D., Bloemer, J., Ghanei, N., Suppiramaniam, V., and Amin,
R. (2018). Signaling Mechanisms of Selective PPARγ Modulators in Alzheimer’s
Disease. Ppar Res 2018, 1–20. doi:10.1155/2018/2010675.
Goya, J., Wong, A. K., Yao, V., Krishnan, A., Homilius, M., and Troyanskaya, O. G.
(2015). FNTM: a server for predicting functional networks of tissues in mouse.
Nucleic Acids Res 43, W182–W187. doi:10.1093/nar/gkv443.
Greene, C. S., Krishnan, A., Wong, A. K., Ricciotti, E., Zelaya, R. A., Himmelstein, D.
S., et al. (2015). Understanding multicellular function and disease with human tissuespecific networks. Nat Genet 47, 569–576. doi:10.1038/ng.3259.
Gu, X., Chen, Y., Zhou, Q., Lu, Y.-C., Cao, B., Zhang, L., et al. (2018). Analysis of
GWAS-linked variants in multiple system atrophy. Neurobiol Aging 67, 201.e1201.e4. doi:10.1016/j.neurobiolaging.2018.03.018.
Guan, Y., Ackert-Bicknell, C. L., Kell, B., Troyanskaya, O. G., and Hibbs, M. A. (2010).
Functional Genomics Complements Quantitative Genetics in Identifying DiseaseGene Associations. Plos Comput Biol 6, e1000991. doi:10.1371/journal.pcbi.1000991.
Hardingham, G. E., and Bading, H. (2010). Synaptic versus extrasynaptic NMDA
receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci
11, 682–696. doi:10.1038/nrn2911.
Hardingham, G. E., Fukunaga, Y., and Bading, H. (2002). Extrasynaptic NMDARs
oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat
Neurosci 5, 405–414. doi:10.1038/nn835.
Henderson, B. W., Greathouse, K. M., Ramdas, R., Walker, C. K., Rao, T. C., Bach, S.
V., et al. (2019). Pharmacologic inhibition of LIMK1 provides dendritic spine
resilience against β-amyloid. Sci Signal 12, eaaw9318.
doi:10.1126/scisignal.aaw9318.
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D.
L., et al. (2015). Neuroinflammation in Alzheimer’s disease. Lancet Neurology 14,
388–405. doi:10.1016/s1474-4422(15)70016-5.
87

HOYER, S., and LANNERT, H. (1999). Inhibition of the Neuronal Insulin Receptor
Causes Alzheimer‐like Disturbances in Oxidative/Energy Brain Metabolism and in
Behavior in Adult Rats. Ann Ny Acad Sci 893, 301–303. doi:10.1111/j.17496632.1999.tb07842.x.
Hu, Y., Zheng, L., Cheng, L., Zhang, Y., Bai, W., Zhou, W., et al. (2017). GAB2
rs2373115 variant contributes to Alzheimer’s disease risk specifically in European
population. J Neurol Sci 375, 18–22. doi:10.1016/j.jns.2017.01.030.
Huang, J., Huang, A., Poplawski, A., DiPino, F., Traugh, J. A., and Ling, J. (2020).
PAK2 activated by Cdc42 and caspase 3 mediates different cellular responses to
oxidative stress-induced apoptosis. Biochimica Et Biophysica Acta Bba - Mol Cell Res
1867, 118645. doi:10.1016/j.bbamcr.2020.118645.
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., et al.
(2008). The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods. J
Magn Reson Imaging 27, 685–691. doi:10.1002/jmri.21049.
Jacomy, M., Venturini, T., Heymann, S., and Bastian, M. (2014). ForceAtlas2, a
Continuous Graph Layout Algorithm for Handy Network Visualization Designed for
the Gephi Software. Plos One 9, e98679. doi:10.1371/journal.pone.0098679.
Jagust, W. J., Bandy, D., Chen, K., Foster, N. L., Landau, S. M., Mathis, C. A., et al.
(2010). The Alzheimer’s Disease Neuroimaging Initiative positron emission
tomography core. Alzheimer’s Dementia 6, 221–229. doi:10.1016/j.jalz.2010.03.003.
Janczura, K. J., Volmar, C.-H., Sartor, G. C., Rao, S. J., Ricciardi, N. R., Lambert, G., et
al. (2018). Inhibition of HDAC3 reverses Alzheimer’s disease-related pathologies in
vitro and in the 3xTg-AD mouse model. Proc National Acad Sci 115, 201805436.
doi:10.1073/pnas.1805436115.
Jansen, I. E., E., S., J., K., W., J., B., M., W., D., S., S., et al. (2019). Genome-wide metaanalysis identifies new loci and functional pathways influencing Alzheimer’s disease
risk. Nat Genet 51, 404–413. doi:10.1038/s41588-018-0311-9.
Jaroudi, W., Garami, J., Garrido, S., Hornberger, M., Keri, S., and Moustafa, A. A.
(2017). Factors underlying cognitive decline in old age and Alzheimer’s disease: the
role of the hippocampus. Rev Neuroscience 28, 705–714. doi:10.1515/revneuro-20160086.
Jassal, B., Matthews, L., Viteri, G., Gong, C., Lorente, P., Fabregat, A., et al. (2019). The
reactome pathway knowledgebase. Nucleic Acids Res 48, D498–D503.
doi:10.1093/nar/gkz1031.

88

Jia, L., Xu, H., Chen, S., Wang, X., Yang, J., Gong, M., et al. (2020). The APOE ε4
exerts differential effects on familial and other subtypes of Alzheimer’s disease.
Alzheimer’s Dementia. doi:10.1002/alz.12153.
Kanehisa, M., and Goto, S. (2000). KEGG: Kyoto Encyclopedia of Genes and Genomes.
Nucleic Acids Res 28, 27–30. doi:10.1093/nar/28.1.27.
Kang, D. E., and Woo, J. A. (2019). Cofilin, a Master Node Regulating Cytoskeletal
Pathogenesis in Alzheimer’s Disease. J Alzheimer’s Dis 72, S131–S144.
doi:10.3233/jad-190585.
Kawaai, K., C., H., Y., K., A., M., T., T., and K., M. (2009). 80K-H interacts with
inositol 1,4,5-trisphosphate (IP3) receptors and regulates IP3-induced calcium release
activity. J Biol Chem 284, 372–80. doi:10.1074/jbc.m805828200.
Kolberg, L., Raudvere, U., Kuzmin, I., Vilo, J., and Peterson, H. (2020). gprofiler2 -- an
R package for gene list functional enrichment analysis and namespace conversion
toolset g:Profiler. F1000research 9, ELIXIR-709.
doi:10.12688/f1000research.24956.2.
Koller, E. J., and Chakrabarty, P. (2020). Tau-Mediated Dysregulation of Neuroplasticity
and Glial Plasticity. Front Mol Neurosci 13, 151. doi:10.3389/fnmol.2020.00151.
Krishna, K., Behnisch, T., and Sajikumar, S. (2016). Inhibition of Histone Deacetylase 3
Restores Amyloid-β Oligomer-Induced Plasticity Deficit in Hippocampal CA1
Pyramidal Neurons. J Alzheimer’s Dis 51, 783–791. doi:10.3233/jad-150838.
Krishnan, A., Zhang, R., Yao, V., Theesfeld, C. L., Wong, A. K., Tadych, A., et al.
(2016). Genome-wide prediction and functional characterization of the genetic basis
of autism spectrum disorder. Nat Neurosci 19, 1454–1462. doi:10.1038/nn.4353.
Lanier, L. M., Gates, M. A., Witke, W., Menzies, A. S., Wehman, A. M., Macklis, J. D.,
et al. (1999). Mena Is Required for Neurulation and Commissure Formation. Neuron
22, 313–325. doi:10.1016/s0896-6273(00)81092-2.
Lanier, L. M., and Gertler, F. B. (2000). From Abl to actin: Abl tyrosine kinase and
associated proteins in growth cone motility. Curr Opin Neurobiol 10, 80–87.
doi:10.1016/s0959-4388(99)00058-6.
Lee, S. H., Harold, D., Nyholt, D. R., Consortium, Anzg., Consortium, I. E., Consortium,
G. and E. R. for A. disease, et al. (2013). Estimation and partitioning of polygenic
variation captured by common SNPs for Alzheimer’s disease, multiple sclerosis and
endometriosis. Hum Mol Genet 22, 832–841. doi:10.1093/hmg/dds491.

89

Leeuw, C. A. de, M., M., J., T., H., and D., P. (2015). MAGMA: generalized gene-set
analysis of GWAS data. Plos Comput Biol 11, e1004219.
doi:10.1371/journal.pcbi.1004219.
Li, M., Xu, Y., Wang, Y., Yang, X.-A., and Jin, D. (2019). Compound heterozygous
variants in MOGS inducing congenital disorders of glycosylation (CDG) IIb. J Hum
Genet 64, 265–268. doi:10.1038/s10038-018-0552-6.
Li, W., Tam, K. M. V., Chan, W. W. R., Koon, A. C., Ngo, J. C. K., Chan, H. Y. E., et al.
(2018). Neuronal adaptor FE65 stimulates Rac1-mediated neurite outgrowth by
recruiting and activating ELMO1. J Biol Chem 293, 7674–7688.
doi:10.1074/jbc.ra117.000505.
Li, Y., and Li, J. (2012). Disease gene identification by random walk on multigraphs
merging heterogeneous genomic and phenotype data. Bmc Genomics 13, S27.
doi:10.1186/1471-2164-13-s7-s27.
Lian, B., liu, M., Lan, Z., Sun, T., Meng, Z., Chang, Q., et al. (2020). Hippocampal
overexpression of SGK1 ameliorates spatial memory, rescues Aβ pathology and actin
cytoskeleton polymerization in middle-aged APP/PS1 mice. Behav Brain Res 383,
112503. doi:10.1016/j.bbr.2020.112503.
Lim, D., Rodríguez-Arellano, J. J., Parpura, V., Zorec, R., Zeidán-Chuliá, F., Genazzani,
A. A., et al. (2016). Calcium Signalling Toolkits in Astrocytes and Spatio-Temporal
Progression of Alzheimer’s Disease. Curr Alzheimer Res 13, 359–369.
doi:10.2174/1567205013666151116130104.
Lin, J. H., Walter, P., and Yen, T. S. B. (2007). Endoplasmic Reticulum Stress in Disease
Pathogenesis. Annu Rev Pathology Mech Dis 3, 399–425.
doi:10.1146/annurev.pathmechdis.3.121806.151434.
Liu, J., Chang, L., Song, Y., Li, H., and Wu, Y. (2019). The Role of NMDA Receptors in
Alzheimer’s Disease. Front Neurosci-switz 13, 43. doi:10.3389/fnins.2019.00043.
Lüscher, C., and Malenka, R. C. (2012). NMDA Receptor-Dependent Long-Term
Potentiation and Long-Term Depression (LTP/LTD). Csh Perspect Biol 4, a005710.
doi:10.1101/cshperspect.a005710.
Ma, Q.-L., Yang, F., Calon, F., Ubeda, O. J., Hansen, J. E., Weisbart, R. H., et al. (2008).
p21-activated Kinase-aberrant Activation and Translocation in Alzheimer Disease
Pathogenesis. J Biol Chem 283, 14132–14143. doi:10.1074/jbc.m708034200.
Mandrekar-Colucci, S., Karlo, J. C., and Landreth, G. E. (2012). Mechanisms Underlying
the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance
90

and Reversal of Cognitive Deficits in a Murine Model of Alzheimer’s Disease. J
Neurosci 32, 10117–10128. doi:10.1523/jneurosci.5268-11.2012.
Mango, D., Saidi, A., Cisale, G. Y., Feligioni, M., Corbo, M., and Nisticò, R. (2019).
Targeting Synaptic Plasticity in Experimental Models of Alzheimer’s Disease. Front
Pharmacol 10, 778. doi:10.3389/fphar.2019.00778.
Marlin, J. W., Chang, Y.-W. E., Ober, M., Handy, A., Xu, W., and Jakobi, R. (2011).
Functional PAK-2 knockout and replacement with a caspase cleavage-deficient
mutant in mice reveals differential requirements of full-length PAK-2 and caspaseactivated PAK-2p34. Mamm Genome 22, 306–317. doi:10.1007/s00335-011-9326-6.
Mastick, G. S., Farmer, W. T., Altick, A. L., Nural, H. F., Dugan, J. P., Kidd, T., et al.
(2010). Longitudinal axons are guided by Slit/Robo signals from the floor plate. Cell
Adhes Migr 4, 337–341. doi:10.4161/cam.4.3.11219.
McQuown, S. C., and Wood, M. A. (2011). HDAC3 and the molecular brake pad
hypothesis. Neurobiol Learn Mem 96, 27–34. doi:10.1016/j.nlm.2011.04.005.
Meyer, D., Dimitriadou, E., Hornik, K., Maintainer, A., and Leisch, F. (2019). e1071:
Misc Functions of the Department of Statistics, Probability Theory
Group (Formerly: E1071). TU Wien. doi:R package version 1.7-3.
Mukherjee, S., Heath, L., Preuss, C., Jayadev, S., Garden, G. A., Greenwood, A. K., et al.
(2020). Molecular estimation of neurodegeneration pseudotime in older brains. Nat
Commun 11, 5781. doi:10.1038/s41467-020-19622-y.
Murk, K., Wittenmayer, N., Michaelsen-Preusse, K., Dresbach, T., Schoenenberger, C.A., Korte, M., et al. (2012). Neuronal Profilin Isoforms Are Addressed by Different
Signalling Pathways. Plos One 7, e34167. doi:10.1371/journal.pone.0034167.
Nott, A., Cheng, J., Gao, F., Lin, Y.-T., Gjoneska, E., Ko, T., et al. (2016). Histone
deacetylase 3 associates with MeCP2 to regulate FOXO and social behavior. Nat
Neurosci 19, 1497–1505. doi:10.1038/nn.4347.
Ottis, P., B., T., M., L., W., L., K., A., de S., D., S., et al. (2013). Aging-induced
proteostatic changes in the rat hippocampus identify ARP3, NEB2 and BRAG2 as a
molecular circuitry for cognitive impairment. Plos One 8, e75112.
doi:10.1371/journal.pone.0075112.
Parrish, R. R., Albertson, A. J., Buckingham, S. C., Hablitz, J. J., Mascia, K. L.,
Haselden, W. D., et al. (2013). Status epilepticus triggers early and late alterations in
brain-derived neurotrophic factor and NMDA glutamate receptor Grin2b DNA
methylation levels in the hippocampus. Neuroscience 248, 602–619.
doi:10.1016/j.neuroscience.2013.06.029.
91

Parsons, M. P., and Raymond, L. A. (2014). Extrasynaptic NMDA Receptor Involvement
in Central Nervous System Disorders. Neuron 82, 279–293.
doi:10.1016/j.neuron.2014.03.030.
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D.
J., et al. (2010). Alzheimer’s Disease Neuroimaging Initiative (ADNI) Clinical
characterization. Neurology 74, 201–209. doi:10.1212/wnl.0b013e3181cb3e25.
Pipatpiboon, N., Pratchayasakul, W., Chattipakorn, N., and Chattipakorn, S. C. (2012).
PPARγ Agonist Improves Neuronal Insulin Receptor Function in Hippocampus and
Brain Mitochondria Function in Rats with Insulin Resistance Induced by Long Term
High-Fat Diets. Endocrinology 153, 329–338. doi:10.1210/en.2011-1502.
Pirttimaki, T. M., Codadu, N. K., Awni, A., Pratik, P., Nagel, D. A., Hill, E. J., et al.
(2013). α7 Nicotinic Receptor-Mediated Astrocytic Gliotransmitter Release: Aβ
Effects in a Preclinical Alzheimer’s Mouse Model. Plos One 8, e81828.
doi:10.1371/journal.pone.0081828.
Pozueta, J., Lefort, R., and Shelanski, M. L. (2013). Synaptic changes in Alzheimer’s
disease and its models. Neuroscience 251, 51–65.
doi:10.1016/j.neuroscience.2012.05.050.
Price, K. A., Varghese, M., Sowa, A., Yuk, F., Brautigam, H., Ehrlich, M. E., et al.
(2014). Altered synaptic structure in the hippocampus in a mouse model of
Alzheimer’s disease with soluble amyloid-β oligomers and no plaque pathology. Mol
Neurodegener 9, 41. doi:10.1186/1750-1326-9-41.
Rajan, K. B., Weuve, J., Barnes, L. L., Wilson, R. S., and Evans, D. A. (2019).
Prevalence and incidence of clinically diagnosed Alzheimer’s disease dementia from
1994 to 2012 in a population study. Alzheimer’s Dementia 15, 1–7.
doi:10.1016/j.jalz.2018.07.216.
Raudvere, U., Kolberg, L., Kuzmin, I., Arak, T., Adler, P., Peterson, H., et al. (2019).
g:Profiler: a web server for functional enrichment analysis and conversions of gene
lists (2019 update). Nucleic Acids Res 47, W191–W198. doi:10.1093/nar/gkz369.
Risacher, S. L., Kim, S., Shen, L., Nho, K., Foroud, T., Green, R. C., et al. (2013). The
role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (EMCI). Front Aging Neurosci 5, 11. doi:10.3389/fnagi.2013.00011.
Ritchie, M. D., Holzinger, E. R., Li, R., Pendergrass, S. A., and Kim, D. (2013). Methods
of integrating data to uncover genotype-phenotype interactions. Nature Reviews
Genetics. doi:doi:10.1038/nrg3868.

92

Rönicke, R., Mikhaylova, M., Rönicke, S., Meinhardt, J., Schröder, U. H., Fändrich, M.,
et al. (2011). Early neuronal dysfunction by amyloid β oligomers depends on
activation of NR2B-containing NMDA receptors. Neurobiol Aging 32, 2219–2228.
doi:10.1016/j.neurobiolaging.2010.01.011.
Sabo, S. L., Ikin, A. F., Buxbaum, J. D., and Greengard, P. (2001). The Alzheimer
Amyloid Precursor Protein (APP) and Fe65, an APP-Binding Protein, Regulate Cell
Movement. J Cell Biology 153, 1403–1414. doi:10.1083/jcb.153.7.1403.
Sadat, M. A., Moir, S., Chun, T.-W., Lusso, P., Kaplan, G., Wolfe, L., et al. (2014).
Glycosylation, Hypogammaglobulinemia, and Resistance to Viral Infections. New
Engl J Medicine 370, 1615–1625. doi:10.1056/nejmoa1302846.
Sattler, R., Xiong, Z., Lu, W.-Y., MacDonald, J. F., and Tymianski, M. (2000). Distinct
Roles of Synaptic and Extrasynaptic NMDA Receptors in Excitotoxicity. J Neurosci
20, 22–33. doi:10.1523/jneurosci.20-01-00022.2000.
Saykin, A. J., Shen, L., Foroud, T. M., Potkin, S. G., Swaminathan, S., Kim, S., et al.
(2010). Alzheimer’s Disease Neuroimaging Initiative biomarkers as quantitative
phenotypes: Genetics core aims, progress, and plans. Alzheimer’s Dementia 6, 265–
273. doi:10.1016/j.jalz.2010.03.013.
Schaeverbeke, J., Gille, B., Adamczuk, K., Vanderstichele, H., Chassaing, E., Bruffaerts,
R., et al. (2019). Cerebrospinal fluid levels of synaptic and neuronal integrity correlate
with gray matter volume and amyloid load in the precuneus of cognitively intact older
adults. J Neurochem 149, 139–157. doi:10.1111/jnc.14680.
Schliebs, R., and Arendt, T. (2011). The cholinergic system in aging and neuronal
degeneration. Behav Brain Res 221, 555–563. doi:10.1016/j.bbr.2010.11.058.
Schuff, N., Woerner, N., Boreta, L., Kornfield, T., Shaw, L. M., Trojanowski, J. Q., et al.
(2009). MRI of hippocampal volume loss in early Alzheimer’s disease in relation to
ApoE genotype and biomarkers. Brain 132, 1067–1077. doi:10.1093/brain/awp007.
Schweinhuber, S. K., Meßerschmidt, T., Hänsch, R., Korte, M., and Rothkegel, M.
(2015). Profilin Isoforms Modulate Astrocytic Morphology and the Motility of
Astrocytic Processes. Plos One 10, e0117244. doi:10.1371/journal.pone.0117244.
Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Clark, C. M., Aisen, P. S., Petersen,
R. C., et al. (2009). Cerebrospinal fluid biomarker signature in Alzheimer’s disease
neuroimaging initiative subjects. Ann Neurol 65, 403–413. doi:10.1002/ana.21610.
Shin, E.-Y., Shim, E.-S., Lee, C.-S., Kim, H. K., and Kim, E.-G. (2009). Phosphorylation
of RhoGDI1 by p21-activated kinase 2 mediates basic fibroblast growth factor93

stimulated neurite outgrowth in PC12 cells. Biochem Bioph Res Co 379, 384–389.
doi:10.1016/j.bbrc.2008.12.066.
Singh, A. K., Kashyap, M. P., Tripathi, V. K., Singh, S., Garg, G., and Rizvi, S. I. (2017).
Neuroprotection Through Rapamycin-Induced Activation of Autophagy and
PI3K/Akt1/mTOR/CREB Signaling Against Amyloid-β-Induced Oxidative Stress,
Synaptic/Neurotransmission Dysfunction, and Neurodegeneration in Adult Rats. Mol
Neurobiol 54, 5815–5828. doi:10.1007/s12035-016-0129-3.
Slováková, J., Speicher, S., Sánchez-Soriano, N., Prokop, A., and Carmena, A. (2012).
The Actin-Binding Protein Canoe/AF-6 Forms a Complex with Robo and Is Required
for Slit-Robo Signaling during Axon Pathfinding at the CNS Midline. J Neurosci 32,
10035–10044. doi:10.1523/jneurosci.6342-11.2012.
Sokka, A.-L., Putkonen, N., Mudo, G., Pryazhnikov, E., Reijonen, S., Khiroug, L., et al.
(2007). Endoplasmic Reticulum Stress Inhibition Protects against Excitotoxic
Neuronal Injury in the Rat Brain. J Neurosci 27, 901–908.
doi:10.1523/jneurosci.4289-06.2007.
Solomon, A., Kivipelto, M., Molinuevo, J. L., Tom, B., Ritchie, C. W., and Consortium,
E. (2018). European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study
(EPAD LCS): study protocol. Bmj Open 8, e021017. doi:10.1136/bmjopen-2017021017.
Song, A., J., Y., S., K., L., R., S., K., W., A., J., S., A., et al. (2016). Network-based
analysis of genetic variants associated with hippocampal volume in Alzheimer’s
disease: a study of ADNI cohorts. Biodata Min 9, 3. doi:10.1186/s13040-016-0082-8.
Spires-Jones, T., and Knafo, S. (2012). Spines, Plasticity, and Cognition in Alzheimer’s
Model Mice. Neural Plast 2012, 319836. doi:10.1155/2012/319836.
Sun, H., Liu, M., Sun, T., Chen, Y., Lan, Z., Lian, B., et al. (2019). Age-related changes
in hippocampal AD pathology, actin remodeling proteins and spatial memory behavior
of male APP/PS1 mice. Behavioural Brain Research 376, 112182. Available at:
http://www.sciencedirect.com/science/article/pii/S0166432819303419.
Supek, F., Bošnjak, M., Škunca, N., and Šmuc, T. (2011). REVIGO Summarizes and
Visualizes Long Lists of Gene Ontology Terms. Plos One 6, e21800.
doi:10.1371/journal.pone.0021800.
Tigaret, C. M., Thalhammer, A., Rast, G. F., Specht, C. G., Auberson, Y. P., Stewart, M.
G., et al. (2006). Subunit Dependencies of N-Methyl-d-aspartate (NMDA) ReceptorInduced α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor
Internalization. Mol Pharmacol 69, 1251–1259. doi:10.1124/mol.105.018580.
94

Trillaud-Doppia, E., and Boehm, J. (2018). The Amyloid Precursor Protein Intracellular
Domain Is an Effector Molecule of Metaplasticity. Biol Psychiat 83, 406–415.
doi:10.1016/j.biopsych.2016.12.015.
Tyler, A. L., A., R., N., K., D., K., C., L., R., H., Z., M., R., et al. (2019). Network-Based
Functional Prediction Augments Genetic Association To Predict Candidate Genes for
Histamine Hypersensitivity in Mice. G3 Genes Genomes Genetics 9, 4223–4233.
doi:10.1534/g3.119.400740.
Um, J. W. (2017). Synaptic functions of the IQSEC family of ADP-ribosylation factor
guanine nucleotide exchange factors. Neurosci Res 116, 54–59.
doi:10.1016/j.neures.2016.06.007.
Varghese, M., Keshav, N., Jacot-Descombes, S., Warda, T., Wicinski, B., Dickstein, D.
L., et al. (2017). Autism spectrum disorder: neuropathology and animal models. Acta
Neuropathol 134, 537–566. doi:10.1007/s00401-017-1736-4.
Verkhratsky, A., Rodríguez-Arellano, J. J., Parpura, V., and Zorec, R. (2017). Astroglial
calcium signalling in Alzheimer’s disease. Biochem Bioph Res Co 483, 1005–1012.
doi:10.1016/j.bbrc.2016.08.088.
Walker, C. K., Greathouse, K. M., Boros, B. D., Poovey, E. H., Clearman, K. R.,
Ramdas, R., et al. (2021). Dendritic Spine Remodeling and Synaptic Tau Levels in
PS19 Tauopathy Mice. Neuroscience 455, 195–211.
doi:10.1016/j.neuroscience.2020.12.006.
Walker, C. K., and Herskowitz, J. H. (2020). Dendritic Spines: Mediators of Cognitive
Resilience in Aging and Alzheimer’s Disease. Neurosci, 107385842094596.
doi:10.1177/1073858420945964.
Wang, R., and Reddy, P. H. (2016). Role of Glutamate and NMDA Receptors in
Alzheimer’s Disease. J Alzheimer’s Dis Preprint, 1–7. doi:10.3233/jad-160763.
Wang, X., Herr, R. A., Rabelink, M., Hoeben, R. C., Wiertz, E. J. H. J., and Hansen, T.
H. (2009). Ube2j2 ubiquitinates hydroxylated amino acids on ER-associated
degradation substrates. J Cell Biology 187, 655–668. doi:10.1083/jcb.200908036.
Wang, Y., C., Z., J., L., Z., Z., X., J., S., X., et al. (2018). PAK2 Haploinsufficiency
Results in Synaptic Cytoskeleton Impairment and Autism-Related Behavior. Cell
Reports 24, 2029–2041. doi:10.1016/j.celrep.2018.07.061.
Wang, Z., Zhang, M., Han, Y., Song, H., Guo, R., and Li, K. (2016). Differentially
disrupted functional connectivity of the subregions of the amygdala in Alzheimer’s
disease. J X-ray Sci Technol 24, 329–342. doi:10.3233/xst-160556.
95

Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., et
al. (2015). 2014 Update of the Alzheimer’s Disease Neuroimaging Initiative: A review
of papers published since its inception. Alzheimer’s Dementia 11, e1–e120.
doi:10.1016/j.jalz.2014.11.001.
Whitwell, J. L., Wiste, H. J., Weigand, S. D., Rocca, W. A., Knopman, D. S., Roberts, R.
O., et al. (2012). Comparison of Imaging Biomarkers in the Alzheimer Disease
Neuroimaging Initiative and the Mayo Clinic Study of Aging. Arch Neurol-chicago
69, 614–622. doi:10.1001/archneurol.2011.3029.
Wickham, H. (2016). ggplot2: Elegant Graphics for Data Analysis. New York: SpringerVerlag Available at: https://ggplot2.tidyverse.org.
Wong, A. K., Krishnan, A., and Troyanskaya, O. G. (2018). GIANT 2.0: genome-scale
integrated analysis of gene networks in tissues. Nucleic Acids Res 46, W65-w70.
doi:10.1093/nar/gky408.
Wong, K., Ren, X.-R., Huang, Y.-Z., Xie, Y., Liu, G., Saito, H., et al. (2001). Signal
Transduction in Neuronal Migration Roles of GTPase Activating Proteins and the
Small GTPase Cdc42 in the Slit-Robo Pathway. Cell 107, 209–221.
doi:10.1016/s0092-8674(01)00530-x.
Wu, M., Z., L., S., M., T., C., R., J., and H., W., W. (2017). Simultaneous inference of
phenotype-associated genes and relevant tissues from GWAS data via Bayesian
integration of multiple tissue-specific gene networks. J Mol Cell Biol 9, 436–452.
doi:10.1093/jmcb/mjx059.
Wyman, B. T., J., H., D., K., C., A., B., M., O., C., E., C., P., et al. (2013).
Standardization of analysis sets for reporting results from ADNI MRI data.
Alzheimer’s Dementia 9, 332–7. doi:10.1016/j.jalz.2012.06.004.
Xu, R., Qin, N., Xu, X., Sun, X., Chen, X., and Zhao, J. (2018). Inhibitory effect of
SLIT2 on granulosa cell proliferation mediated by the CDC42-PAKs-ERK1/2 MAPK
pathway in the prehierarchical follicles of the chicken ovary. Sci Rep-uk 8, 9168.
doi:10.1038/s41598-018-27601-z.
Yao, V., Kaletsky, R., Keyes, W., Mor, D. E., Wong, A. K., Sohrabi, S., et al. (2018). An
integrative tissue-network approach to identify and test human disease genes. Nat
Biotechnol 36, 1091–1099. doi:10.1038/nbt.4246.
Yao, X., Jingwen, Y., Kefei, L., Sungeun, K., Kwangsik, N., L., R., Shannon, et al.
(2017). Tissue-specific network-based genome wide study of amygdala imaging
phenotypes to identify functional interaction modules. Bioinformatics 33, 3250–3257.
doi:10.1093/bioinformatics/btx344.
96

Yu, S. Y., Wu, D. C., and Zhan, R. Z. (2010). GluN2B subunits of the NMDA receptor
contribute to the AMPA receptor internalization during long-term depression in the
lateral amygdala of juvenile rats. Neuroscience 171, 1102–1108.
doi:10.1016/j.neuroscience.2010.09.038.
Yu, W.-F., Guan, Z.-Z., Bogdanovic, N., and Nordberg, A. (2005). High selective
expression of α7 nicotinic receptors on astrocytes in the brains of patients with
sporadic Alzheimer’s disease and patients carrying Swedish APP 670/671 mutation: a
possible association with neuritic plaques. Exp Neurol 192, 215–225.
doi:10.1016/j.expneurol.2004.12.015.
Zhao, N., Liu, C.-C., Qiao, W., and Bu, G. (2018). Apolipoprotein E, Receptors, and
Modulation of Alzheimer’s Disease. Biol Psychiat 83, 347–357.
doi:10.1016/j.biopsych.2017.03.003.
Zhou, Q., Zhao, F., Lv, Z., Zheng, C., Zheng, W., Sun, L., et al. (2014). Association
between APOC1 Polymorphism and Alzheimer’s Disease: A Case-Control Study and
Meta-Analysis. Plos One 9, e87017. doi:10.1371/journal.pone.0087017.
Zhu, X., S., W., L., Y., J., J., X., Y., Y., L., et al. (2017). HDAC3 negatively regulates
spatial memory in a mouse model of Alzheimer’s disease. Aging Cell 16, 1073–1082.
doi:10.1111/acel.12642.

97

MULTI-NETWORK APPROACHES TO NETWORK-BASED GENE
REPRIORITIZATION
Jeffrey L. Brabec1, Montana Kay Lara1, Anna L. Tyler2, J. Matthew Mahoney 1,2*, and the
Alzheimer’s Disease Neuroimaging Initiative†
1. University of Vermont
Department of Neurological Sciences
89 Beaumont Avenue
Burlington, VT 05401
2. The Jackson Laboratory
600 Main Street
Bar Harbor, ME 04609

*Correspondence:
J. Matthew Mahoney
Matt.Mahoney@jax.org

98

Introduction
Genome-wide association studies (GWAS) use single-nucleotide polymorphisms
(SNPs) that vary across the human population to identify disease risk loci by statistically
associating SNPs to phenotypes. However, the causal effect of mapped SNPs on disease
risk, if any exists, cannot be resolved from the GWAS data alone. Moreover, the most
statistically significant SNP in a region––the index SNP––may only be linked to the
causal variant, meaning that it is only correlated with the presence of the truly causal
variant or variants. Thus, the interpretation of SNP associations from GWAS requires
functional prioritization to rank variants or genes near the index SNP as most likely to
causally influence the phenotype. A powerful set of approaches to functional
prioritization is network-based functional prediction (NBFP) (Guan et al., 2010; Greene
et al., 2015; Wu et al., 2017). In NBFP, one uses gene interaction networks to identify
gene subnetworks that are enriched for disease-associated genes and score all genes in the
genome by their network connections to disease genes (Guan et al., 2010; Greene et al.,
2015; Wu et al., 2017). There are many gene interaction networks covering many
contexts, including gene transcription networks (Marbach et al., 2016), protein-protein
interaction networks (Tomkins and Manzoni, 2021), and tissue- and cell-type-specific
functional networks (Wong et al., 2018). For example, the popular NetWAS tool uses
tissue- and cell-type-specific functional networks as input features for machine learning
classifiers to rank genes according to their connectivity to disease risk genes. The choice
of input network amounts to selecting a context in which causal variants are expected to
be relevant and can have a significant influence on the output gene rankings. For complex
diseases, there may even be multiple relevant networks. In this study, we extend the
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NetWAS approach to allow multiple input networks to aggregate evidence across many
contexts to improve functional prioritization of GWAS candidate genes. We call our
approach multi-network NBFP (mNBFP).
In contrast to network-based approaches, another popular functional prioritization
strategy is to augment SNP-phenotype associations with SNP-molecule associations, such
as expression quantitative trait loci (eQTLs) or protein QTLs (pQTLs), which are
significant associations between SNPs and molecular abundance that we will call
generically molecular QTLs (mQTLs). Such mQTLs are mechanistically interpretable
and conform to the expectation that most common variants for complex human disease
influence gene regulation, as opposed to modifying protein sequence [REF]. However,
mQTL analysis is not sufficient to prioritize casual variants for two distinct reasons. First,
to complete the causal path from variant to molecule to phenotype, one must establish
that the target molecule of an mQTL is itself functionally related to the disease
phenotype. Second, the molecular data must come from the correct context, including the
correct cell type and pathogenic time point, in which the causal variant is relevant. In
many cases, this context is unknown and may even be inaccessible, such as during brain
development. Furthermore, even when accessible, mQTL data is expensive and
challenging to acquire. Whether or not mQTL-based prioritization can be surrogated by
inexpensive in silico network-based approaches is an open question.
We applied mNBFP to a meta-GWAS of Alzheimer’s disease (AD). AD is a
genetically complex neurological disorder involving all major cell types of brain (Lopez
et al., 2019). Despite robust statistical associations of variants in 42 genes to AD, the
mechanisms by which these genes influence AD outcomes is unknown. Indeed, even the
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relevant cell types remain controversial, and all cell types are likely involved in some
potentially distinct capacity (De Strooper and Karran, 2016). Thus, AD presents a robust
use-case where we can test the hypothesis that fusing multiple disease-relevant functional
networks can improve genome-wide gene rankings. In this study, we used mNBFP with
multiple brain cell type networks, including neurons and glia. Using recently published
AD GWAS data, we compared the output of mNBFP to mQTL-based rankings of genes
near newly detected genome-wide significant loci for AD.
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Methods
Network Processing, Feature Selection, and Model Training
The network edge-lists for the neuron, glia, and astrocyte networks were obtained from
the online repository HumanBase (https://hb.flatironinstitute.org/download; ‘neuron_top’,
‘glia_top’, and ‘astrocyte_top’). Briefly, these networks were generated using a
regularized Bayesian knowledge integration based on tissue ontology and a combination
of gene expression datasets from the Gene Expression Omnibus (Barrett et al., 2013)
representing 20,868 conditions (Greene et al., 2015). Each functional network is a
weighted network, where each pair of genes (gi, gj) is linked with a weight, 𝑊𝑔𝑖 𝑔𝑗 ,
encoding the predicted probability that those genes functionally interact in that tissue. We
define a feature vector, fg, for each gene, g, in the genome as the vector of weights
connecting g to the n AD-GWAS genes, 𝑝1 , … , 𝑝𝑛 (i.e., positive examples),

𝑓𝑔 = [𝑊𝑔𝑝1 , … , 𝑊𝑔𝑝𝑛 ].

Each feature vector was dimension-reduced using a k-medoids method. In contrast to a kmeans method, k-medoids chooses real data points as centers or medoids. Using this
method, we reduced each feature set down to the 500 most representative genes. The
dimension-reduced networks were then merged together to form the final multi-network
with 1500 features and 25,825 variables. In addition to the multi-network, we processed
each single network into a dimension-reduced feature-set form to perform single-network
NBFP.
Using these feature vectors, we trained an ensemble of (linear) support vector
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machine (SVM) classifiers to distinguish between AD-GWAS genes and the rest of the
genes in the genome. Formally, this problem is an instance of positive-unlabeled (PU)
learning (PU), as we only have positive examples of AD-relevant genes (i.e., GWAS
hits), but the status of all other genes is unknown. In the PU learning setting, we can treat
all unlabeled examples as negatives for the sake of training the model, with the
understanding that many unlabeled examples are likely AD-associated genes (Elkan and
Noto, 2008). We performed 10-fold nested cross-validation (CV) to ensure independent
training and testing sets, as our positive examples our limited to the AD-GWAS genes.
Hyperparameters were tuned in the inner CV loop and tested in the outer CV loop. The
data were initially split into 10 equal folds, the outer loop, and stratified so that a
proportional set of positive and unlabeled genes were present in each fold. Subsequently,
each fold was split into testing and training sets. The training set of each fold was further
split into 25 bootstraps, the inner-loop, again stratified on the class of each gene, which
were also split into testing and training sets. The models in the inner-loop, were trained
using a balanced set of positive and unlabeled examples (down-sampling the unlabeled
set) as putative negatives. Each inner-loop SVMs was cross-validated over the 25
bootstraps to optimize its cost hyperparameter, C, over a grid, as described previously
(Tyler et al., 2019). Each model Mi assigns each gene, gj, a model-based, real-valued
prediction score Mi(gj), where scores above 0.5 correspond to high confidence that the
gene is a positive example and scores below 0.5 correspond to low confidence. To
determine a gene’s predicted score across all models, we calculated the logarithmic mean
of its prediction score. To normalize prediction scores across models prior to
aggregation, we computed an unlabeled-predicted-positive rate (UPPR) for each model,
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Mi, and gene, gj, as

UPPR ij =

#{𝑔 ∈ 𝑈𝑛𝑙𝑎𝑏𝑒𝑙𝑒𝑑 | 𝑀𝑖 (𝑔) > 𝑀𝑖 (𝑔𝑗 )}
#{𝑔 ∈ 𝑈𝑛𝑙𝑎𝑏𝑒𝑙𝑒𝑑} | 𝑀𝑖 (𝑔) > 𝑀𝑖 (𝑔𝑗 )} + #{𝑔 ∈ 𝑈𝑛𝑙𝑎𝑏𝑒𝑙𝑒𝑑 | Mi(𝑔𝑗 ) > 𝑀𝑖 (𝑔)}

,

where ‘#’ denotes the cardinality of a finite set. The UPPR is the PU-learning equivalent
of the false positive rate, where lower values indicate higher confidence that a gene is
functionally associated with the AD GWAS genes. We took the average of UPPR over all
models and took the negative logarithm to obtain a final functional score, FS(gj)
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1
𝐹𝑆(𝑔𝑗 ) = − log10 (
∑ 𝑈𝑃𝑃𝑅𝑖𝑗 ) .
100
𝑖=1

The functional score ranges from zero to infinity, with higher values indicating greater
confidence. Models were trained using the e1071 R package (Meyer et al., 2019).

Top Functional Network Analysis
NBFP identifies functional candidates based on their connections to the ADGWAS genes. To determine how the top functional candidates interact with one another
in the component cell-type networks, we performed module detection and pathway
enrichment analysis. For all three cell-type networks, we extracted the subnetworks of
genes which reached a functional score greater than two (i.e., average UPPR < 0.01).
Modules were identified using spinglass community detection implemented in R. The
resulting networks were visualized using pheatmap and genes in each cluster were
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ordered by their degree. Pathway enrichment for Gene Ontology Biological Process
(GO:BP) terms (Ashburner et al., 2000; Carbon et al., 2018) for each module was
performed using the g:GOSt function from the gprofiler2 R package (Kolberg et al.,
2020). High-level annotations for each cluster were annotated on the heatmap, as well as
the top three genes in each cluster by degree.

Functional Prediction Validation
The set of gold standard AD genes is dominantly GWAS risk genes, which makes
it difficult to validate functional predictions. A recent AD meta-GWAS study performed
functional prioritization using a novel method, and identified several novel AD candidate
genes (Bellenguez et al., 2022). Therefore, we decided to do a comparative analysis of
the top functional candidates from our two studies. They performed a two-stage analysis
which incorporated sample information from several consortia and datasets including:
EADB, GR@ACE, EADI, GERAD/PERADES, DemGEne, Bonn, the Rotterdam study,
the CCHS study, NxC, and UKBB for the Stage I analysis and ADGC, CHARGE, and
FinnGenn for the Stage II analysis (Bellenguez et al., 2022). Individuals for this study
were of European descent, or designated as non-white Hispanics in the incorporated
datasets. The Stage I analysis included 39,106 clinically diagnosed AD cases, 46,828
proxy-AD cases (based on a questionnaire asking whether the individual’s parents had
dementia), and 401,577. The Stage II analysis included 25,392 AD cases and 276,086
controls.
In Stage I, a meta-analysis of the data from the included studies was conducted.
They identified variants which reached a Stage I p < 10e-5, classifying them as an index
variant, and defined a ±500 kb window around each. After merging the windows
105

together, they performed an iterative clumping procedure to assign variants to clumps of
the index variants, starting with the index variant with the lowest p-value. Variant which
reached a Stage I p < 10e-5 and were located within the 1Mb window of the current index
variant were assigned to that window. This process was repeated until all variants were
assigned to clumps. For the Stage II analysis, results from the studies from both stages
were combined in a fixed-effect meta-analysis. Follow-up variants needed to have the
same direction of effect in both stages and a Stage II p-value < 0.05. Genome-wide
significant candidates were identified from this set (n = 42 significant loci). Variant-togene mapping was performed using the MAGMA tool (deLeeuw et al., 2015). Functional
scores were calculated for genes within a 2Mb window of each significant locus. Their
functional score incorporated: 1) variant annotation, 2) eQTL-GWAS integration, 3)
sQTL-GWAS integration, 4) protein QTL (pQTL)-GWAS integration, 5) mQTL-GWAS
integration, 6) histone acetylation QTL (haQTL)-GWAS integration, and 7) APP
metabolism [REF]. Full descriptions of each domain can be found in their methods
section. Functional prediction resulted in 55 genes. We obtained summary statistics for
these genes from their paper and replicated their 2MB window search, but instead
prioritized by our functional score opposed to their QTL based method.
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Results
mNBFP improves over single-networks to predict AD-risk genes
We performed four parallel NBFP runs using the three brain-cell networks,
Neuron, Glia, and Astrocyte: one each for the dimension-reduced cell networks, and one
for a multi-network fusion of those networks. During training, all network models
performed approximately the same on average (astrocyte = 0.65, glia = 0.65, multinetwork = 0.65, neuron = 0.62) with the neuron network having the lowest average AUC,
which was significantly lower than the multi-network average AUC (p = 4e-8; Fig. 11A).
In testing, the three single-networks performed, on average, the same as they did in
training, with the neuron results showing modest improvement (astrocyte = 0.65, glia =
0.65, neuron = 0.64; Fig. 11B). In testing, the multi-network significantly outperformed
each of the single networks, with an average AUC of .78 (neuron p = 1.2e-10, astrocyte p
= 1.1e-8, glia p = 3.8e-9; Fig. 11B). Furthermore, across all outer CV folds, the multinetwork had the lowest variance, 5.16e-4, of all the models (neuron = 5.89e-4, astrocyte
= 8.6e-4, glia = 8.1e-4), suggesting that the multi-network produces more consistent
models.
These results demonstrate that mNBFP can more robustly predict AD risk gene
networks compared to single-network NBFP. In particular, the increase in AUC for
mNBFP shows that the multi-network model has significantly fewer unlabeled genes
(i.e., non-true-positive genes) that are highly ranked by the SVM, suggesting increased
confidence of the predicted disease association for those that are highly ranked compared
to single-network models.
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Figure 11: The NBFP model performance results. A) In training all models performed the same, on average
(astrocyte = 0.65, glia = 0.65, multi-network = 0.65, neuron = 0.62). The mNBFP performance was
significantly better than the neuron performance in training (p = 4e-8). B) In testing, the mNBFP
significantly outperformed the single-network examples (neuron p = 1.2e-10, astrocyte p = 1.1e-8, glia p =
3.8e-9) the average performance of which stayed similar to the training performance (astrocyte = 0.65, glia
= 0.65, neuron = 0.64). The mNBFP approach also had the lowest performance variance, indicating more
consistent models.

Top Functional Candidates Coalesce into Hubs
To functionally annotate the pathways used by the multi-network model, we
performed a modularity and enrichment analysis of the subnetworks of high-scoring
genes for each source network. Spinglass-community detection and ontology analysis of
the neuron network identified four modules of genes enriched for Gene Ontology terms
involved in cell adhesion and motility, amyloid regulation, corticoid regulation, and
immune regulation, respectively (Fig. 12). Each of these pathways are implicated in AD
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pathology, especially amyloid regulation. We sorted genes within each module by their
degree to identify hub genes. The hub genes in the neuron network clusters were: STK10
(cell adhesion and motility), GRN (amyloid regulation), NRP2 (corticoid regulation), and
PHLDA1 (immune regulation). Interestingly, none of these genes were in the original true
positive training set, though they appear to not only be hubs for their module but are
densely connected to the other top functional candidates. The gene NRP2 had the unique
behavior of low functional scores in both the neuron (0.684) and glial (0.893) models and
a good score in the astrocyte model (1.47), but a much larger score in the multi-network
model (2.1). The additional information from all three networks has the potential to
improve our candidate prioritization by nominating genes which may have important
disease roles across several tissue types, but may be missed if only a single network is
used where they play more minor roles.
Community detection and ontology analysis identified three modules in the
astrocyte network involved in apoptosis, cellular responses to stress, and immune
regulation, respectively. The hub genes for these clusters were: IL12A (apoptosis), CCL2
(cellular response to stress), and GREM1 (immune regulation) (Suppl. Fig. 1).
The same analysis identified three modules in the glia network involved in cell
motility and adhesion, cell death regulation, and regulation of stress response,
respectively. The hub genes for these clusters were GREM1 (cell motility and adhesion),
IL12A (cell death regulation), DUSP5 (regulation of stress response) (Suppl. Fig. 2).
Again, none of these hub genes were in the original set of true-positives used to train the
model, though similarly to the top-astrocyte network, the hub genes IL12A and GREM1
appear to be connected to a majority of the other top functional candidates in the glia
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network.
These results demonstrate that the network features used by multi-network NBFP
to classify AD GWAS genes are enriched for AD-related biological processes and that
the multi-network model assigns high scores to AD-relevant hub genes, including novel
candidates that were not present in the training data.

Figure 12: Heatmap of connections between top functional candidates in the neuron network. Spinglasscommunity detection identified four modules in the top neuron network. Genes in each module were
ordered by degree. High-level summaries of the pathway enrichments of these modules indicate
enrichments for cell adhesion and motility, amyloid regulation, corticoid regulation, and immune
regulation. The top-degree genes of the cell adhesion and motility module include STK10, EMP3, and
NNMT. The top amyloid regulation genes include GRN, RNF123, and LTBP3. Top corticoid regulation
genes include NRP2, MBOAT2, and BACE1. The top-degree immune regulation genes are PHLDA1,
CAMK2N1, and PDIA3.
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Multi-network NBFP predicts novel GWAS genes
Given recently reported associations of some non-true-positive hub genes to AD,
we sought to systematically evaluate whether mNBFP was able to identify novel AD
gene associations. The recently published study from Bellenguez et al. implemented a
novel functional prioritization method, briefly described in the methods section, to
identify disease-gene candidates based on genome-wide significant risk variants
(Bellenguez et al., 2022). Their two-stage GWAS meta-analysis incorporated data from a
number of different AD consortia (Methods). The Stage I analysis included 39,106
clinically diagnosed AD cases, 46,828 proxy-AD cases (based on a questionnaire asking
whether the individual’s parents had dementia), and 401,577 controls. The Stage II
analysis included 25,392 AD cases and 276,086 controls. All participants for this study
were of European descent, or designated as non-white Hispanics in the incorporated
datasets. They identified 42 genome-wide significant loci containing 55 novel putative
AD gene associations which passed their prioritization criteria with 31 of those genes
classified as Tier 1 and 24 as Tier 2. A gene received a Tier 1 ranking if the relative
difference between its prioritization score and the other genes in its the locus was at least
20% and it obtained a score ≥ 4. If this threshold was not met, the highest ranked gene in
the locus was assigned to Tier 2 (Bellenguez et al., 2022).
To determine the concordance between our functional score and the candidates
nominated by Bellenguez et al., we scored all genes within the same 2 Mb windows to
obtain an mNBFP functional score-based ranking. The mNBFP functional score is a
continuous measure with no hard significance cutoff. Therefore, we assessed
concordance of the two candidate prioritization methods by comparing the Bellenguez et
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al. top candidate(s) in each window to the top 1, 3, and 5 top functional score candidates
(Table 3). To determine if the mNBFP approach had greater concordance with the
Bellenguez study than a single-network approach, we performed the same comparison
with the single-network results. Comparison of a single top candidate per window
revealed that our method shared 10 out of 55 top gene predictions with the Bellenguez et
al. study.

Table 3: Table summarizing concordant top-functional candidates between our method and that developed
by Bellenguez et al. We examined overlaps for the top 1, 3, and 5 functional candidates.

Network

1 Top Candidate

3 Top Candidates

5 Top Candidates

Multi-Network

10

17

22

Neuron

8

15

22

Astrocyte

8

19

24

Glia

4

15

23

This concordance is highly non-random based on a permutation test where
functional scores for genes in each locus are randomly permuted (p < 2e-5). (A
permutation test was used because some windows overlapped, rendering analytic tests
inapplicable.) Notably, for all 10 concordant candidates, the candidate gene was the
closest gene to the index SNP. Beyond the top candidates, 17 candidates from Bellenguez
et al. were ranked in the top three by multi-network functional score and 22 were ranked
in the top five (Table 3). This high concordance with the Bellenguez et al. candidates was
particularly pronounced in the multi-network model. Using the functional score from
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each of the single networks we obtained concordances of 8 (neuron), 8 (astrocyte), and 4
(glia) (Table 3). Together, these results demonstrate that the multi-network-based
functional score is sensitive to functional information otherwise contained in direct data
from patient brain tissue. Importantly, none of these top-5 candidate genes were part of
the positive training set for the NBFP models, demonstrating that unlabeled-predicted
positive genes from mNBFP are highly enriched for functionally relevant AD genes.
In contrast to the concordant genes, there were 31 cases where the mNBFP topranked gene had a functional score greater than one while the candidate from Bellenguez
et al. had a functional score less than one (Table 5). Among these, several top candidates
by multi-network NBFP have pre-existing literature evidence for association to AD such
as ARFGAP1, MBOAT2, MARCKS, and OAS1 (Kimura et al., 2000; Fujita et al., 2016,
2018; Lee et al., 2019; Salih et al., 2019; Brito et al., 2020; Feitosa et al., 2020; Padhi et
al., 2022).
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Discussion
In this study we developed multi-network NBFP as a simple and powerful
extension of NBFP techniques, like NetWAS (Greene et al., 2015), for gene
prioritization. Starting with set of nominally positive input genes (e.g., significant GWAS
genes), NBFP ranks all genes in the genome by how strongly they connect to positive
genes in a functional network. This network-based ranking is distinct from the statistical
signal that produced the input list (e.g., GWAS p-value) and is often much more strongly
enriched for disease-relevant biological signals (Guan et al., 2010; Greene et al., 2015). A
priori, there are two criteria such a ranking should satisfy. First, the ranking should
achieve good classification performance on the positive training inputs. Second, the
“false positive” predictions from the model should, in fact, be biologically meaningful
inferences. In this study, we demonstrated that by combining information from multiple
disease-relevant cell-type networks, we can improve over single-network NBFP on both
criteria simultaneously; mNBFP had a higher AUC than single-network NBFP and was
more highly concordant with functional prioritizations of gene candidates in novel AD
risk loci than any single-network model. By these benchmarks, our multi-network
method is more conservative in predicting an AD association outside the input positive
set, and such predictions align with functional prioritizations that account for extensive
molecular and functional evidence that is difficult and costly to generate (Tam et al.,
2019). Not only did the multi-network approach perform significantly better than the
single-network approaches, but it also had the lowest variability among all the models,
showing that the multi-network is able to consistently build good models of functional
significance. The success of multi-network NBFP in AD is a strong proof-of-concept for
114

other complex genetic disorders.
In addition to methodological advances, the prioritizations of our multi-network
model are of significant interest in AD. AD has become one of the most prevalent
diseases of late life, but the genetic etiology is far from understood. Despite the
significant concordance between our rankings with Bellenguez et al. in their recently
identified risk loci, our method disagreed strongly with their candidate in 31 cases (Table
5). These discordant cases are potentially instructive about the strengths and weaknesses
of the two approaches to candidate prioritization. The Bellenguez et al. approach
emphasizes molecular QTLs that align with disease risk loci and in vitro gene
knockdown screens of amyloid precursor protein (APP) metabolism as positive evidence
of AD association. However, in AD, QTLs can only be ascertained in post-mortem brain
tissue, which could miss a critical time point during development or pathogenesis when
the causal gene is active. Likewise, a strong in vitro association with APP metabolism
may be sufficient for functional relevance to AD but is not necessary. In contrast, our
approach uses existing functional interaction networks that were trained using large
compendia of mostly gene co-expression data (Greene et al., 2015; Wong et al., 2018).
These networks effectively encode the emergent co-expression structure of different cell
types and tissues, but do not have any a priori association to AD-specific biology. Thus,
in ranking candidates in the Bellenguez et al. loci, our multi-network method seeks
candidates within each locus that are connected with positive training set genes.
Considering these differences, the overlap of ten genes as top candidates by both ranking
approaches is highly surprising. Looking at these ten genes carefully, we notice they have
more in common than just top ranking in both methods. By the Bellenguez et al. method,
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each of these genes reached Tier 1 status (i.e., strong evidence as a causal gene), each had
an AD-associated eQTL, and they all contained the index SNP defining their
prioritization window. Interestingly, only one of the ten–– APP–– had a measured effect
on APP metabolism (Bellenguez et al., 2022).

Table 4: Summary table of concordant top functional candidates from our study and from Bellenguez et al.

Top Functional Candidates Mediating Amyloid Plaque Deposition
Of the ten shared genes, GRN had the highest functional score and was a hub gene
in the “amyloid regulation” module in the neuron network. The protein product of this
gene, as well as its many smaller cleavage productions, are involved in a range of
pathways including embryogenesis, tumorigenesis, inflammation, wound repair, and
lysosome function (Chitramuthu et al., 2017). Genetic variations in GRN are associated
with a range of neurological disorders including fronto-temporal lobar degeneration
(FTLD) and fronto-temporal dementia (FTD) (Chitramuthu et al., 2017; Wang et al.,
2021b). Loss of both alleles of the gene led to the development of the disease neuronal
ceroid lipofuscinosis (NCL) which is a lysosomal storage disease, which may give us
insight into how its dysfunction may contribute to AD pathology (Chitramuthu et al.,
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2017). It is hypothesized that high-levels of A can interrupt lysosomal signaling
pathways, perhaps interfering with the mechanisms that would clear this toxic protein
aggregates (Polanco and Götz, 2018). In a 2020 study, prior to GRN achieving genomewide significance, researchers observed that GRN and a number of risk and sub-threshold
AD genes showed increase expression in an APPswe/PS1L166P mouse in response to high
levels of A (Sierksma et al., 2020). GRN is a strong functional candidate for AD.
The gene APP had the third highest functional score of the shared genes. APP
codes for the protein which is eventually cleaved into A and is therefore one of the most
important genes of AD (Sabo et al., 2001; Lanoiselée et al., 2017; Trillaud-Doppia and
Boehm, 2018; Lopez et al., 2019; Kim and Bezprozvanny, 2021). Several mutations in
APP have been known to contribute to familial inheritance for years, but it only achieved
genome-wide significance recently (Wightman et al., 2021). Since APP is such a welldocumented AD gene, we know that it is an integral part of disease subnetworks, with
documented interactions with the biggest AD risk gene, APOE (Huang et al., 2017). APP
is not a concordant gene in the neuron, glia, and astrocyte models until we compare the
top 3 functional candidates to the Bellenguez et al. gene. This gene’s strong mNBFP
functional score indicates that integrating the information from the three networks the
machine-learning algorithm to better identify the disease subnetworks.
The other eight genes with shared top priority have varied strength of associations
to AD in the literature (Table 4). CTSH, TSPAN14, NCK2 and PLEKHA1 have all been
implicated in AD or related disorders in recent genetic and protein screens (Haljas et al.,
2018; Ou et al., 2021; Schwartzentruber et al., 2021). The genes BLNK and CTSB may
act in the same pathway as GRN as they have both been observed to have altered
117

expression in response to A or roles in regulating lyosomal autophagy (Sierksma et al.,
2020; Zhang et al., 2020). Despite varying levels of literature evidence in support of roles
in AD, the replication of these genes as top functional candidates in two independent
studies warrants further studies to determine mechanisms of action and specific roles in
AD pathophysiology.

Top Functional Candidate Divergences
While a significant number of top candidates were shared between the two
methods, there was a much larger set of functional predictions (n = 31) for which the two
scores diverged (Table 5). To determine the differences between the two sets and the
biological support for our functional predictions, we performed a PubMed literature
search in which we used the gene name + “Alzheimer’s” or “neuron” to identify genes
which had previously been studied in the context of AD or played roles in other
neurological disorders. Though there were many genes with neurological associations, we
have chosen to focus on a few with the highest functional scores, and a clear involvement
in dysfunctional AD pathways.

MARCKS is an Early AD Gene
On chromosome 6, our mNBFP method prioritized MARCKS (FS = 1.90) in
contrast to the Bellenguez et al. candidate HS3ST5 (FS = 0.04). MARCKS has been
extensively studied in association with AD (Table 5) (Kimura et al., 2000; Su et al., 2010;
Fujita et al., 2016, 2018; Liu et al., 2018; Tanaka et al., 2020; Chen et al., 2021).
MARCKS encodes the protein myristoylated alanine-rich C-kinase substrates that
catalyzes cross-linking of actin filaments and is involved in diverse cellular pathways
including cell adhesion and phagocytosis (Chen et al., 2021). Actin cross-linking is
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required for neurite outgrowth and dendritic spine stability and phosphorylation of
MARCKS is known marker of neurite degeneration in early stages of Parkinson’s
Disease (PD), and may be a viable marker for early-stage AD pathology (Fujita et al.,
2018; Okazawa, 2021). In AD, Fujita et al. have reported that in response to high levels
of A, glutamatergic neurons release the protein HMGB1, which binds to TLR4 and
triggers the sustained phosphorylation of MARCKS causing neurite degeneration (Fujita
et al., 2016). They suggest that a monoclonal antibody targeting HMGB1 could be an
effective treatment for preclinical AD to delay disease onset. In a subsequent study, the
same group explored the broader effects of pMARCKS in cortical neurons of 5XFAD
mice and observed decreased nuclear levels of Yes-associated protein (YAP) by
immunohistochemistry due to increased sequestration in cytoplasmic amyloid plaques
(Tanaka et al., 2020). YAP is a critical transcriptional regulator of homeostasis and its
sequestration seems to drive early-AD necrosis (Tanaka et al., 2020).
In contrast to MARCKS the Bellenguez candidate, HS3ST5 (heparan sulfateglucosamine 3-sulfotransferase) has only 9 PubMed results, with only one of those
containing evidence for a neurological association as a potential risk gene in a
schizophrenia GWAS (Wang et al., 2013). The balance of evidence for this locus
suggests that MARCKS is a superior functional candidate for the chromosome 6 locus.
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Table 5: Divergent functional candidates between the two methods. Evidence for association to AD or
another neurological disorder is provided by PubMed ID.
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ARFGAP1 as a mediator of excitotoxicity in AD and PD
ARFGAP1 (FS = 2.8) had the highest functional score of any locus in this
analysis, making it an excellent functional candidate for the chromosome 20 locus over
its Bellenguez et al. counterpart, LIME1 (0.33). ARFGAP1 codes for the protein ADP
ribosylation factor GTPase activating protein 1 which is a Golgi apparatus-associated
protein which hydrolyzes the ADP ribosylation factor 1-bound GTP (Feng et al., 2021).
This activity is required for the proper dissociation of coat proteins, which help transport
vesicles from the Golgi to the ER (Feng et al., 2021). ARFGAP1 has been shown to be
up-regulated in late stages of mild-cognitive impairment (MCI), though the precise
functional implications of this finding are not clear (Brito et al., 2020).
ARFGAP1’s main neurological association is with PD. ArfGAP1 is known to
physically bind to the kinase site of leucine-rich repeat kinase 2 (LRRK2) (Stafa et al.,
2012; Xiong et al., 2012), whose kinase activity is a driving factor in the loss of
dopaminergic neurons in PD (Watanabe et al., 2020; Usmani et al., 2021). In 2012, Xiong
et al. showed that LRRK2 and ArfgGAP1 have a reciprocal regulatory relationship. If
expressed separately, ArfGaP1 or LRRK2 will induce cell death, however if expressed
together, ArfGAP1 binds to LRRK2 and promotes the hydrolysis of GTP which causes a
decrease in LRRK2’s kinase activity and autophosphorylation. In turn, LRRK2
phosphorylates ArfGAP1 which inhibits further GTPase activation (Stafa et al., 2012;
Xiong et al., 2012). While these two proteins are tightly intertwined, they may not
necessarily be the mitigating factors of the other’s dopaminergic neuron toxicity,
meaning there are likely other, yet unidentified mediators of these two proteins individual
pathogenicity (Liu et al., 2008; Xiong et al., 2012). Due to its high functional score and
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integral role in PD-related neurodegeneration, ARFGAP1 is a strong risk gene candidate
in the chromosome 20 locus, and may even be a druggable therapeutic target.
OAS1 Regulates Inflammatory Signals in Response to A levels
The gene OAS1 was the top functional candidate for the mNBFP method (FS =
1.46) at the chromosome 12 locus. The corresponding Bellenguez et al. gene was RITA1
(FS = 0.70). RITA1 has no literature association to AD or other neurological disorders.
Recently, Salih et al. nominated OAS1 as a candidate risk gene for amyloid deposition
based on increased expression of the mouse ortholog Oas1a in response to amyloid levels
(Salih et al., 2019). Lee et al. showed that OAS1 has anti-inflammatory activity in
macrophages, which is triggered through TLR3 and TLR4 signaling (Lee et al., 2019). It
has been shown that microglial activation in AD is partly triggered through the binding of
aggregated amyloid plaques to TLR4 receptors on microglia (Yang et al., 2020). Roy et
al. showed that Oas1a is up-regulated in amyloid plaques and classified it as an
“interferon stimulated gene” in their murine AD model (Roy et al., 2020). Magusali et al.
showed that high levels of OAS1 were critical for suppressing pro-inflammatory signals
in myeloid cells (Magusali et al., 2021). Taken together, these results strongly implicate
OAS1 in AD-related neuroinflammation and support it as a functional candidate in the
chromosome 12 locus.

Multi-network identifies disease genes across populations
Beyond the risk loci from Bellenguez et al., any gene with a high functional score
is predicted to be associated with AD. One such gene was the cytokine IL12A (FS =
3.70), which was a hub gene in modules from both the astrocyte and glia networks
(Suppl. Fig 1 and 2). Our pathway analysis showed that its two modules were enriched
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for “apoptosis” and “regulation of cell death” pathways. IL12A has primarily been
studied for its role in cancers and auto-immune disorders (Tsai et al., 2009; Roszak et al.,
2012; Ruffell et al., 2014; Teos and Alevizos, 2017), but it has recently also been
associated with AD risk gene in a Han Chinese population (Zhu et al., 2014). Notably, it
has strong connections to OAS1, discussed above, as well as CXCL2, another immunemodulating chemokine which is the second most densely connected gene in the astrocyte
“apoptosis” module. Thus, our network results implicate IL12A as a potential immune
effector of cell death in AD.
This result highlights an important distinction between a risk gene, which is at
least partially dependent on the genetic background of a population, and a disease gene,
which plays a mechanistic role in a disease. The goal of NBFP is to extrapolate from risk
genes, given by GWAS associations, to a broader set of disease genes. Ideally, this
extrapolation should lose the population specificity of its input set and identify new genes
that are nevertheless involved in the disease process. In the case of IL12A, we see that we
can extrapolate from risk genes derived from in a European-descent population, to predict
potentially novel disease genes, which, in this case, have polymorphisms influencing
disease risk in a different population.

In this chapter we have shown that a multi-network approach to NBFP
significantly outperforms the single-network method. We have further validated our
predictions by comparing top functional predictions within risk loci with a recently
published study by Bellenguez et al. where we showed incredible coherence with 10 of
their top functional candidates. Finally, our literature search has shown that many of our
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top functional candidates, including those which drastically diverged in functional score
from the Bellenguez et al. candidates, are integral members of biological pathways which
are intricately involved in the onset and progression of AD. In the next chapter we will
discuss a combined-ranking method to identify potential therapeutic candidates for
repositioning for use in early-AD.
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Supplemental Figures

Supplemental Figure 1: Heatmap of connections between top functional candidates in the astrocyte
network. Spinglass-community detection identified three modules in the top astrocyte network. Genes in
each module were ordered by degree. High-level summaries of the pathway enrichments of these modules
indicate enrichments for apoptosis, cellular response to stress, and immune regulation. The top-degree
genes of the apoptosis module include IL12A, CXCL2, and BACE1. The top cellular response to stress
genes include CCL2, ITIH3, and DUSP5. Top immune regulation genes include GREM1, TNC, and ATF3.
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Supplemental Figure 2: Heatmap of connections between top functional candidates in the glia network.
Spinglass-community detection identified three modules in the top glia network. Genes in each module
were ordered by degree. High-level summaries of the pathway enrichments of these modules indicate
enrichments for cell mobility and adhesion, cell death regulation, and regulation of stress response. The
top-degree genes of the cell mobility and adhesion module include GREM1, CXCL2, and CCL2. The top
cell death regulation genes include IL12A, BACE1, and SPSB1. Top regulation of stress response genes
include DUSP5, ITIH3, and EPS8.
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Introduction
Alzheimer’s disease (AD), a devastating neurodegenerative disorder, is poised to
be one of the biggest public health issues of the next thirty years. By 2050, fifty-million
people worldwide are expected to suffer from the disease and though worldwide cases are
currently a fraction of that, issues of long-term care and disease maintenance are already
compounded by the lack of any disease modifying therapies and the sheer cost of AD
drug development (Fig. 3, Chapter 1). Currently approved drugs like donepezil and
rivastigmine provide some relief to cognitive deficits, but do nothing to delay or halt the
pathological progression of the disease (Briggs et al., 2016; Cummings et al., 2020). This
disease places a heavy burden on patients and their families which will only be lifted with
novel therapeutic approaches which can both slow pathological progression and provide
relief for cognitive deficits.
As AD is a progressive disease, the earlier a treatment course can start, the greater
the chance of mitigating damage from neuroinflammation and saving crucial neurons and
glia to prevent cognitive decline. Current methods for target identification are temporally
agnostic. A risk locus from a Genome-Wide Association Study (GWAS) may indicate a
target to explore, but the risk association for the gene provides no information about
which pathways it may function in or at which point during a person’s life it is having its
biggest effects (Fig. 13). Some genetic risk factors for disease may influence early
development leading to varied cell populations in critical AD structures like the
hippocampus. As one ages, other genetic factors come into play, mediated by education,
early-childhood socialization, diet, and other crucial environmental factors. By the time a
patient begins to notice symptoms of cognitive decline, the treatable genetic factors are
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likely far removed from the initial risk genes that drove early-brain development.

Figure 13: Schematic representing the effects of genetic and environmental variables on brain development
and disease onset.

To determine the best treatment options for the patient when they walk in for a
consultation, we need methods that integrate genetic risk with the differential genetic
regulation driving early disease pathology to identify disease genes, that when targeted,
will improve the cognitive and pathological phenotypes of AD. GWAS p-value alone
provides no functional context and state-of-the art network-based functional prediction
(NBFP) studies are limited by their use of a single tissue network. Our earlier work
proposed a multi-network NBFP (mNBFP) approach which integrates information from
three brain-cell specific networks to identify robust functional candidates (Chapter 3).
Functional score alone is blind to developmental state so we propose a combined ranking
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of mNBFP functional score and early-disease pathology differential expression to
identify robust therapeutic targets for the early-AD intervention. We have identified
several candidate compounds and proteins which may slow progression and improve
cognitive state. We also show that a currently approved AD treatment may promote some
genetic signatures that are up-regulated in early-AD, making it a poor therapeutic
candidate.
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Methods
Single-nucleus RNAseq analysis
Summary statistics for differentially expressed genes were obtained from a 2019
study examining brain-cell-specific differential expression using single-nucleus RNAseq
(snRNAseq) (Mathys et al., 2019). After quality control to filter out low-quality reads and
cells, 17,926 protein coding genes were profiled in 70,634 nuclei. They identified
differentially expressed genes using two separate statistical tests. They first conducted a
cell-level analysis using the Wilcoxon rank-sum test with an FDR correction. The second
test was a Poisson mixed model to account for the individual of origin for the cells and
any other unwanted sources of variability. A gene had to obtain a corrected p < 0.05 in
both models to be considered differentially expressed. Excitatory neurons were the
dominantly represented cell-type, followed by oligodendrocytes, inhibitory neurons,
astrocytes, oligodendrocyte precursor cells (OPCs) and finally microglia (Fig. 14). The
differentially expressed genes were mostly unique to the cell type with some overlaps
between inhibitory and excitatory neurons and astrocytes (Fig. 15).
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Figure 14: TSNE plot showing the general proportions of the total cell population that each cell-type
represented. Excitatory neurons were the largest group, followed by oligodendrocytes, inhibitory neurons,
astrocytes, OPCs and microglia.
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Figure 15: Upset plot showing overlaps of differentially expressed genes between the different cell-types.
Most differentially expressed genes were unique to a cell-type but there was some overlap between the
neuron types and the oligodendrocytes and astrocytes. OPCs and microglia were excluded from this plot as
they only had 18 and 10 differentially expressed genes, respectively, and did not overlap with any of the
other cell types. Y-axis is on a log to aid in readability of smaller bars.

Multi-Network-based Functional Prioritization
Standard NBFP uses a single disease-relevant tissue-specific gene interaction
network to perform disease-gene prioritization. In the previous chapter, we showed that
an mNBFP approach significantly outperformed the standard single-network method at
prioritizing the positive class of AD genes (Fig. 11). The full methodology is reported in
the previous chapter, but briefly, the three cell-type networks were dimension-reduced
using a k-medoids feature-selection algorithm and merged together. The positive class
was defined as the set of genes which reached a nominal level of significance (p < 0.01)
from a large AD MetaGWAS study resulting in n = 739 genes (Jansen et al., 2019).
Functional candidates were identified using a linear SVM which analyzes the connections
to the positive class of genes to identify disease subnetworks.
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Multi-objective prioritization
In Chapter 2, we discussed how a multi-objective prioritization (MOP) could
prioritize endophenotype-specific functional candidates in AD. The MOP leverages
ranking information from two independent sources to answer a biological question that
neither set of data could answer alone. The mNBFP promotes robust functional
candidates for AD while the early-AD differential expression identifies early-disease
functional changes. An MOP of the two scores can identify early-AD differentially
expressed genes why may influence cognitive and behavioral phenotypes due to their
proximity to disease risk genes.
To integrate mNBFP functional scores with early disease differential expression,
we computed a combined score based on the empirical joint cumulative density function
(CDF) of the two scores. Specifically, every gene, g, had a functional score FS(g), and a
positional score PS(g) = -log10(pg), where pg is the p-value for g in the early-AD
differential expression dataset. To quantify how highly ranked a gene, gj, is along both
measures simultaneously, we used the value of the empirical joint CDF as a combined
score, CS(gj),

CS(g j ) =

#{g ∈ Genome| FS(g) < FS(g j ) & PS(g) < PS(g j )}
,
N

where N is the number of genes in the genome. Note that this is equivalent to the
probabilistic definition using the empirical joint distribution of the two scores. Thus, the
combined score represents the probability that a randomly chosen gene in the genome
will score lower on both measures than gj.
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Connectivity Map
The Connectivity Map was first proposed by Lamb et al. in 2006 (Lamb et al.,
2006). In its original instantiation, the Connectivity Map took drug signatures from
various cell types and compiled them into a library which could be queried. Differential
expression signatures (up tags and down tags) are submitted to the platform and it
generates a connectivity score based on how well the drug signatures correlated or anticorrelated with your expression signatures (Lamb et al., 2006). In the case of a major
disease like AD, we would be looking for drugs which anti-correlated with the disease
signal as those would likely ameliorate the debilitating effects of the disease.
The Connectivity Map has since been updated to the L1000 LINCS system which
has allowed the Broad Institute to significantly expand its library of cells, drugs, and
perturbagens (Subramanian et al., 2017). We wanted to compare the drug results from the
combined score to those derived from just differential expression alone. Therefore, we
submitted two separate analysis jobs. There is a technical limit of 150 up and 150 down
tags so each dataset was filtered accordingly. While we have differential expression for
several different cell-types, our previous work and the over-representation of excitatory
neurons in the expression data led us to focus on those results. Results for the other celltypes can be found in the supplementary figures. As our analysis focused on excitatory
neurons, we restricted the cell type signatures only include neurons and neuron precursor
cells. We explored the overlap of each drug set by looking at the top shared drugs that
anti-correlated with our signatures as well as the uniquely anti-correlated drugs for each
score type to identify differences in the kinds of drugs each score type would identify.
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Results
Multi-Objective Prioritization Promotes Early Pathology Targets
We hypothesized that a multi-objective prioritization of genes with high
functional scores and early-AD differential expression would be the strongest candidates
for therapeutic targeting. For up-regulated MOP candidates, we identified several genes
involved in tumor suppression including ACTN4, LTBP3, PTPRU, PTOV1, and DUSP8
(Fig. 16B). DUSP8 is also involved in regulation of hippocampal size and behavior and
plays a role in insulin sensitivity which is a known risk pathway for AD (Baumann et al.,
2019; Ding et al., 2019; Schriever et al., 2020). Several down regulated functional
candidates are involved in apoptotic pathways (RABAC1) (Kim et al., 2019),
neurodegenerative disorders (TUBA4A) (Chia et al., 2018; Mol et al., 2021), and
increased risk for AD development due to alcohol consumption (ACTG1) (Hoffman et al.,
2019) (Fig. 16A). Notably, there are several genes which have p-values on the order of
less than 10e-40, but these do not attain high functional scores and rank very low under
the MOP. While these genes have significant expression changes from the control
baseline, they are perhaps more distal to the actual disease risk and may not be effective
targets for disease modifying therapies.
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Figure 16: MOP for up and down regulated early-AD functional candidates for excitatory neurons. The
MOP prioritizes genes with the best combined scores for either axis. This means that more significant
genes or stronger functional candidates may get overlooked in favor of more modest-scoring genes.

MOP identifies candidate drugs for AD-repositioning
Using the LINCS database, we identified several drugs of interest. First, the
proteins NSA2 and PER2 and the drug pargyline were top candidates for both differential
expression and combined score (Fig. 17). However, none of them had as low as score as
the protein AP1B1 which was the best drug for the combined score, and was the best
scoring drug overall. The top unique treatment for the differential expression was the
protein DHX29 which plays a role in transcription initiation (Pisareva and Pisarev, 2016).
Our focus was on identifying novel therapeutic candidates, but we were also
curious where previously approved AD drugs fell on this list. From a literature search we
identified tacrine (which has been discontinued as an AD drug due to extreme
hepatotoxicity), donepezil, memantine, galantamine, and rivastigmine as either current, or
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past approved AD treatments. Of the five drugs only one, donepezil, had a signature in
the neuron and neuron progenitor cells and both its MOP and differential expression
connectivity scores were positive, indicating that it would induce a gene expression
signature more similar to that in early-AD pathology. This may indicate that our
methodology could have precluded donepezil from consideration as an AD treatment.

Figure 17: LINCS connectivity score comparison plot. The top drugs for each individual score and top
drugs shared by the two scores are labeled. In the upper right quadrant, we have also labeled donepezil, a
current AD drug treatment which anti-correlates with both score types.
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Discussion
We implemented a combined-score prioritization integrating functional scores
from our mNBFP functional predictions and p-values from early-AD snRNAseq data.
This method identifies genes proximal to disease risk in the brain-cell networks with
altered expression states compared to controls. Targeting these genes with repositioned
drugs may help to slow pathological progression and ameliorate cognitive outcomes. We
have also shown that utilizing a combined ranking of genes can promote genes with
stronger connectivity scores through LINCS than differential expression alone, though
further studies are necessary to confirm the efficacy of all proposed candidates. The
protein AP1B1 is the top candidate based the LINCS connectivity score, though we also
discuss the potential of the proteins NSA2, PER2, and DHX29 as well as the drug
pargyline.

Treatment with AP1B1 to Mitigate Neuroinflammation
The adaptor protein complex AP-1 beta 1 subunit (AP1B1) protein is involved in
cellular migration and intracellular sorting (Boyden et al., 2019). Recent experiments
conducted on the function of the AD-risk gene TREM2 in microglia has exposed AP1B1
as an important protein in driving anti-inflammatory activity in microglia (Liu et al.,
2020a). Increased TREM2 expression supports anti-inflammatory signaling in microglia.
The recent work by Liu et al. (2020) in an in vitro model has shown that induction of an
inflammatory signal by lipopolysaccharide (LPS) binding to toll-like receptor 4 (TLR4)
drives pro-inflammatory activity in microglia. Other recent work has indicated that TLR4
senses A and drives a similar program of microglia-induced neuroinflammation (Liu et
al., 2020b). Increased TLR4 signaling downregulates TREM2 expression which leads to
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decreased levels of STAT6, a key protein that supports anti-inflammatory signaling by
IL-4. This leads to decreased expression of the genes Arg1 and Ap1b1 which are key
signaling proteins involved in the maintenance of anti-inflammatory activity in microglia.
Long-term maintenance of this pro-inflammatory signal by A binding to TLR4,
in addition to long-term effects of oxidative stress due to an inflammatory environment,
could contribute to loss of neurons and the resulting cognitive phenotypes of AD.
Treatment of patients with this protein at an early stage of the disease may help to
mitigate early damage caused by a sustained pro-inflammatory microglial state. This may
lead to a halt, or at the very least a dramatic slowing, of pathological progression, perhaps
buying patients years of cognitive functionality. Pairing this treatment with a plaque
mitigation strategy with limited side-effects, and maintenance of a healthy life style, may
help to stop progression of the disease and make management of cognitive symptoms
easier.

Management of Cognitive Decline via PER2
PER2 is a clock-controlled gene, meaning it is expressed in a circadian pattern
(Oyama et al., 2021). While polymorphisms in the gene primarily lead to cancer and
sleep disorders, some studies suggest a role in long-term potentiation (LTP) and synaptic
plasticity which could contribute to deficits in cognitive performance in patients with
MCI or AD (Wang et al., 2009a; Mazzeo et al., 2021). Work by Bessi et al. (2021)
suggests that the C111G polymorphism in PER2 influences cognitive reserve and
cognition. Previous work has shown that the expression and effects of PER2 are localized
to specific regions of the brain like the hippocampus and amygdala (Bessi et al., 2021).
While several studies have suggested that certain polymorphisms of PER2 may
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contribute to variations in cognitive reserve, the exact direction of effect remains unclear,
as well as the influence of cognitive reserve on AD which is still a debated subject (Wang
et al., 2009a; Bessi et al., 2018; Mazzeo et al., 2021).
The biggest effect may be in sleep disturbances. One study which performed
intra-hippocampal injections of amyloid showed abnormal expression of PER2,
suggesting this gene may play a role in amyloid-driven sleep disturbances experienced by
many AD patients (Wang et al., 2016a). These sleep disturbances may detrimentally
affect other factors controlling LTP and immune regulation which may exacerbate
molecular phenotypes of AD. The precise activity of PER2 is still not fully understood so
additional experiments to understand its role in AD pathophysiology are necessary to
determine its potential for therapeutic intervention. However, treatment with a healthy
form of the protein may help regulate sleep disturbances and cognitive deficits driven by
pathogenic PER2 polymorphisms.
NSA2 Influences Glucose Levels and TGF Signaling
NSA2 is a nuclear protein involved in cell-cycle regulation and proliferation and is
involved in ribosomal subunit biogenesis (Paternoga et al., 2020). The gene product has
been shown to be unregulated in cases of diabetic nephropathy but the functionality of
NSA2 is still not fully understood, and its potential effect on neurons and glia is not clear
(Shahni et al., 2013). The most likely pathway to effect of AD phenotypes is through the
effect of NSA2 on TGF1 signaling. NSA2 acts upstream of TGF1, and loss of proper
NSA2 functionality may contribute to diabetic nephropathy development through loss of
downstream TGF1 activity (Shahni et al., 2013; Caraci et al., 2018). TGF1 is an antiinflammatory cytokine and is known to support memory formation and synaptic plasticity
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in the brain (Caraci et al., 2018; Linnemann and Lang, 2020). Lower levels of the protein
have been observed in AD patients and those with depression (Linnemann and Lang,
2020). Treatment with functional NSA2 may help normalize TGF1 expression and limit
cognitive decline. However, more research needs to be conducted to understand the
function of NSA2 in the brain and to ensure the safety and efficacy of using this protein
as a therapeutic agent.

Pargyline and Rasagiline: Disease Modifiers via MAO-A Inhibition
Pargyline is a mono-amine oxidase (MAO) inhibitor with anti-hypertensive
effects(Ojha et al., 2021). This function may have several benefits. It is known that one
risk-factor for dementias is hypertension (Lennon et al., 2020). A recently published
study suggests that treatment of AD patients with a comaurin-pargyline compound has
the dual effects of inhibiting MAO-A activity as well as A aggregation (Yang et al.,
2017). Although previous attempts to treat the aggregation of A have proved ineffective,
if the intervention is applied early enough, mass aggregation could be prevented,
potentially mitigating chronic inflammation and excitotoxicity of the brain.
Pargyline is chemically very similar to a Parkinson’s drug, rasagiline, which is an
irreversible MAO-B inhibitor. Rasagiline recently underwent a phase II clinical trial in
which its effects were assessed in an AD population (Matthews et al., 2021). Efficacy
was judged based on improvements in brain metabolism in critically affected brain
regions as well as several cognitive measures. Much like many other drugs that have been
used in AD, it did significantly improve metabolism measured by florodeoxyglucose
(FDG)-PET in the treatment patients, but there were no significant improvements in
cognition, though some reported improvements in quality-of-life (Matthews et al., 2021).
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Critically, there were few adverse side-effects reported by the treatment group.
Notably, drugs like Aduhelm, which was recently approved for treatment of AD,
can have serious side-effects like edema (Sevigny et al., 2016a; Howard and Liu, 2020).
If drugs like rasagiline and pargyline, which are highly specific to mono-amine oxidase
compounds, can limit off-target effects and reduce levels of inflammatory biomarkers,
they could be strong candidates to reposition to AD cases, perhaps in combination with
other therapeutics.

DHX29 as a Potential Transcriptional Regulator in AD
DHX29 codes for a D-box helicase which is involved in the initiation of
translation (Pisareva and Pisarev, 2016). With 29 PubMed search results, DHX29 has no
previously studied roles in AD or neurological disorders. While it appears to be involved
in the proper transcription of SIRT6, which has been observed to have decreased
expression in AD there are no direct connections between DHX29 and AD (Wang et al.,
2021a). Upregulation of SIRT6 reduced DNA damage in a mouse model of AD, therefore
decreased expression of DHX29 may lead to decreased translation of downstream
proteins which may be sustaining a healthy brain-state (Jung et al., 2016). This protein’s
path forward as a potential therapeutic requires further inquiry into its potential role in the
development and progression of AD.

Donepezil, a Potentially Poor Therapeutic Candidate
Donepezil is currently one of the gold-standard treatments for AD. Using our
MOP, we observed that donepezil more closely correlates with the disease expression
signals as indicated by its LINCS score (Fig. 17). Donepezil has documented cases offtarget effects to the GI system such as nausea, vomiting and muscle cramps (Rogers and
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Friedhoff, 1996; Atri, 2019). While these are not specifically CNS effects, in cultured
neuronal cells our results indicate that it induces a more similar pattern of expression to
that observed in early-pathology AD.
In the previous chapter, we observed that our prioritization was concordant with
another recently published study examining functional prioritization in AD (Bellenguez
et al., 2022). Given this concordance we are inclined to hypothesize that if a functional
prioritization approach had been applied when donepezil was originally recommended as
an AD drug, these methods may have indicated that it would be a poor candidate for
treatment for AD. While there are many patients who have benefited from treatment with
donepezil, both its on and off-target effects vary from patient to patient. Though any
treatment will show varied efficacy across the population, and ideal therapeutic would
minimize this variation.

Conclusions
The multi-objective prioritization allows us to leverage the early time-point of the
expression data and the functional score from the broader mNBFP analysis to identify
differentially expressed genes that are proximal to the disease risk and would therefore
make ideal therapeutic targets. The combined score necessarily contains a large fraction
of the differential expression signal since genes with larger magnitude p-values have the
potential to have a higher combined score. However, as we observe with the downregulated combined score set of genes in Fig. 16, there are many genes with p-values of
10e-20 or less which have low combined scores and are not included in the final set. In
fact, there is no overlap in the gene sets for either the 150 up or 150 down tags. Despite
this, the results from Connectivity Map indicate that the top genes in either case are
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strong candidates. Here, were present a set of hypotheses for therapeutics recommended
by two different genetic ranking methods. A follow-up study could explore the efficacy
of each of these therapeutics in an AD model mouse such as the 5XFAD to determine
benefits to cognitive outcomes and pathological progression.
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Supplemental Figures

Supplemental Figure 3: MOP for up and down regulated early-AD functional candidates for inhibitory
neurons. The MOP prioritizes genes with the best combined scores for either axis. This means that more
significant genes or stronger functional candidates may get overlooked in favor of more modest-scoring
genes.
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Supplemental Figure 4: MOP for up and down regulated early-AD functional candidates for astrocytes. The
MOP prioritizes genes with the best combined scores for either axis. This means that more significant
genes or stronger functional candidates may get overlooked in favor of more modest-scoring genes.
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Supplemental Figure 5: MOP for up and down regulated early-AD functional candidates for astrocytes. The
MOP prioritizes genes with the best combined scores for either axis. This means that more significant
genes or stronger functional candidates may get overlooked in favor of more modest-scoring genes.
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CHAPTER 5: CONCLUSION
Unlike some other devastating neurological disorders, such as Dravet’s Syndrome
(Lagae, 2020), AD pathogenicity is not driven by a single gene. Though APOE, APP and
other genes have major effects on the heritability of the disease, therapeutics designed to
target their pathways have, so far, failed (Rogers and Friedhoff, 1996; Lanoiselée et al.,
2017; Howard and Liu, 2020; Serrano-Pozo et al., 2021). In more recent cases, drugs
have been designed to target the underlying pathological phenotypes of the disease,
namely amyloid plaque build-up. Many recent drugs have tried to target the amyloid
aggregation that some have argued is the initiation point of neurodegeneration (Rogers
and Friedhoff, 1996; Wilkinson et al., 2001; Sevigny et al., 2016a). While Aduhelm
resulted in a significant decrease in amyloid levels in the brains of participants, that did
not lead to a commensurate improvement in cognitive function in AD patients (Sevigny
et al., 2016a; Howard and Liu, 2020).
Older drugs, like donepezil, which is currently prescribed to the majority of AD
patients, were designed to ameliorate cognitive deficits in patients (Briggs et al., 2016).
These drugs offer only temporary benefit as they do nothing to alter the underlying
pathological progression of the disease (Briggs et al., 2016). We are left with two
imperfect treatment options: one which targets the main quality of life deficits offering
short term relief, and the other which helps clear a major pathological biomarker with no
apparent benefit to cognitive outcomes and an increased likelihood of adverse events in
the group that needs the drug the most.
Throughout this dissertation we have argued that one of the major issues with
therapeutic development in AD is that disease risk and the treatable dysfunction do not
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necessarily overlap on the same target. Our current methods for gene prioritization,
namely GWAS and RNAseq, are limited by their lack functional (GWAS), risk
(RNAseq), and temporal context. Novel genetic identification methods like networkbased functional prediction have provided a mechanism to extrapolate from the risk and
differentially expressed genes to the rest of the genetic interaction network to identify
robust functional candidates (Greene et al., 2015). Here, we have shown that innovations
on these methods that incorporate diverse data streams and an expanded list of networks,
can further bolster the list of candidate genes and increase our confidence in the validity
of those genes.
Higher AUCs and lower p-values increase our statistical confidence in these
models, but true validation comes from what is known about these candidates in the
literature and what can be confirmed in follow-up validation studies. Relying on a low pvalue or false-positive rate, does not guarantee that a candidate will have any effect on
disease status or outcomes. We have tried to increase the confidence in our top candidates
by assessing their biological significance using pathway analysis and literature reviews.
These deep dives into the literature revealed that neuronal excitotoxicity plays a large
role in neurodegeneration in the hippocampus and the amygdala and that one of the top
treatment candidates for stages of AD could play a role in regulating microglia-induced
excitotoxicity. Of course, this information only sets up the validation hypotheses.
The past twenty years have seen an exponential increase in the volume and
diversity of genetic data available to researchers. The tools to analyze that data are
equally numerous and diverse, requiring the development of a whole new field of
bioinformatics. While many of the tools have been designed for user accessibility, more
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advanced tools require dedicated scientists who are often sequestered from bench work.
Validation of these candidates takes a diverse team of bioinformaticians and bench
scientists to identify the most likely candidates and test them in vitro and in vivo. This
requires teams of scientists willing to dabble in unfamiliar technical territory, and
research and educational programs with integrated curricula.
Our current methods for therapeutic identification and development have left AD
patients without good recourse post-diagnosis. While computational approaches cannot
provide sure-fire candidates, they streamline the process of therapeutic development and
help focus research efforts on the best possible therapeutic candidates. We hope that as
these methods further mature in the coming years, they will incorporate additional data
streams and diverse expert opinions to ensure that genetic targets that we identify and
follow-up on have the greatest likelihood of yielding an actionable therapeutic
mechanism.
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